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ABSTRACT 
Current guidelines recommend dual-arm blood pressure measurement when 
screening all patients for hypertension, however the prevalence and reliability of systolic 
and diastolic inter-arm differences (sIADs and dIADs) are unclear in young, healthy 
adults. Furthermore, no study has investigated ambulatory sIADs and dIADs in this 
population. This study examined the prevalence and reliability of sIADs and dIADs>5, 10, 
15, and 20mmHg, using sequential and simultaneous resting, and sequential ambulatory 
blood pressure measurements, in 18 healthy adults aged 20-38 years. Key findings were: 
First-day prevalence of resting sIADs>10mmHg was 5.6% (p<0.05; sequential) and 11.1% 
(p<0.05; simultaneous), while no resting dIADs of this magnitude were found. First-day 
ambulatory sIADs>10mmHg were observed in 44.4% (p<0.05) of participants. With 
respect to reliability, although non-significant (p>0.05), prevalence of resting and 
ambulatory sIADs and dIADs decreased on a second day, and resting sIADs>10mmHg 
disappeared altogether. Further research is required to clarify the clinical relevance of 
these findings. 
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1.1 HYPERTENSION AND CARDIOVASCULAR RISK 
1.1.1. Definition, Epidemiology, and Importance of Hypertension 
Hypertension (HT), a condition characterized by sustained elevations in resting systolic 
blood pressure (SBP) above 139 millimeters of mercury (mmHg), and/or in resting diastolic 
blood pressure (DBP) above 89mmHg, measured at the brachial artery, afflicts greater than 1 
billion people worldwide.1 It has been identified as one of the most preventable causes of 
cardiovascular disease (CVD) and related mortality,2, 3, 4 being responsible for 9.4 million deaths 
each year.1 In 2013, the World Health Organization deemed HT a global health crisis, 
highlighting its prevention as a cornerstone in the effort to reduce death from non-communicable 
diseases.1 Primary (essential) HT makes up 95% of all cases, is complex and multi-factorial 
having both genetics and lifestyle as prominent players in its etiology, and is recognizable by the 
absence of secondary causes.5, 6 Conversely, secondary hypertension is the direct result of some 
other disease or condition (e.g., endocrine, renal, or neurovascular diseases; tumours; and 
pregnancy), usually making its cause readily identifiable and in many cases reversed with 
treatment.6, 7  
Risk factor assessment in primary care is therefore important for the prevention, 
diagnosis, and targeted treatment of primary HT.6 Risk factors include family history, as well as 
genetic and lifestyle-related physiological and psychological features of the individual, such as: 
obesity; smoking; insulin-resistance; excessive alcohol consumption; high salt intake; low 
potassium intake; and stress.6, 8, 9  
Although brief elevations in blood pressure are normal and reflective of diurnal rhythms 
and periods of increased activity or psychological stress, sustained elevations can lead to early 
structural remodeling of cardiac and vascular muscle (i.e., ventricular hypertrophy, increased 
arterial stiffness, and altered geometry of the ventricular contractile apparatus) in response to 
increased ventricular load and vascular shear stress.5 Secondary HT also results in similar 
pathological structural adaptations.10 Combined with subsequent elevation of the homeostatic set-
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point as new pressures are “accepted” as normal,5 these structural adaptations yield an 
increasingly high mean arterial pressure (MAP), placing the cardiovascular system under further 
stress and at heightened risk of CVD, cardiovascular death, myocardial infarction, and stroke.11 
Further evidence for the relationship of elevated blood pressure (even within the normal 
range) to CVD-related mortality comes from a meta-analysis of prospective observational data 
from one million adults, aged 40 years and older. It revealed that, as risk of vascular-related death 
increases both progressively and linearly with age, this risk more than doubles between the ages 
of 40 and 69 years with each rise of approximately 20mmHg SBP or 10mmHG DBP above 
values of 115/75mmHg.12 A strong association exists between increases in blood pressure and 
age-specific mortality rates from stroke, ischemic heart disease and other vascular diseases,12 
demonstrating the importance of the relationship between elevated blood pressure and CVD-
related mortality. Given the strength of this relationship, management of HT presents an 
important target for reducing premature illness and death. 
In direct follow-up to this meta-analysis, the data presented on the relationship of SBP to 
cardiovascular-related mortality were used to calculate the potential reduction in unnecessary 
deaths in the United Kingdom (UK) if all cases of systolic HT could be controlled to 140mmHg.13 
The results revealed that such control could prevent 21,400 deaths from stroke and 41,400 deaths 
from ischemic heart disease each year in the UK alone. The authors further estimate that 
controlling all cases of systolic HT could prevent an additional 125, 600 non-fatal cardiovascular 
events per year in the UK. Given that prevalence and control of blood pressure are similar in 
many other countries,13 such prevention not only represents an important opportunity for 
improvement of worldwide health and longevity, but also for significant reduction of economic 
burden.14 
As early, accurate diagnosis of HT is crucial to its management,15 effective screening 
procedures in primary care are of the utmost importance. Blood pressure measurement is the most 
commonly performed examination in primary care,16 yet while prevalence of HT continues to 
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rise,17 many cases remain undiagnosed or poorly controlled,3, 18 resulting in inadequate treatment 
worldwide.19  
This review therefore presents common problems associated with clinical blood pressure 
measurement and describes a specialized technique (i.e., dual-arm measurement) that has the 
potential to greatly improve both screening for HT and risk assessment for cardiovascular 
morbidity and mortality. Dual-arm blood pressure measurement is the major focus of this 
discussion and is dealt with in some detail in terms of recent evidence and present controversies 
surrounding its usefulness. Finally, current gaps in the literature regarding dual-arm blood 
pressure measurement are addressed. First, however, in order to grasp the compelling evidence 
for the necessity of dual-arm measurement techniques in clinical practice, diagnostic criteria for 
HT and standard methods of blood pressure measurement must be understood.  
1.2 DIAGNOSIS OF HYPERTENSION 
1.2.1 Measuring Blood Pressure 
Direct measurement of blood pressure is the most accurate method of assessment, and 
involves percutaneous insertion of a catheter into the radial artery. Beat-to-beat SBP, DBP, and 
MAP (weighted average of SBP and DBP, such that MAP ≈ 1/3(SBP) + 2/3(DBP))20 are 
calculated via use of a pressure transducer attached to the catheter.21 However, because this 
procedure is highly invasive, involves specialized training, and is expensive,22 more practical 
non-invasive techniques exist. Two techniques are readily employed in clinical practice: 1) 
sphygmomanometric auscultation and 2) automated oscillometry. Both of these measurements are 
taken at the brachial artery, the standard site for blood pressure measurement in clinical 
practice.23 
Clinical Blood Pressure Measurement 
Sphygmomanometric Auscultatory Blood Pressure Measurement 
Despite recent criticism regarding its accuracy,15 sphygmomanometric auscultation has 
been the accepted gold-standard of clinical blood pressure measurement for over 100 years.24 It 
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involves inflation of a brachial cuff to a value exceeding SBP, momentarily occluding blood flow. 
The brachial or radial pulse is palpated (at the antecubital fossa or wrist, respectively) prior to 
inflation, and via the use of a stethoscope, the assessor listens for the return of a pulse as the cuff 
gradually begins to deflate.25 The first appearance of a clear tapping sound indicates this return, 
and represents the first phase in a series of distinct auditory segments known as Korotkoff sounds. 
Cuff pressure is then recorded, being representative of maximal (i.e., systolic) blood pressure. As 
cuff pressure further decreases, the strength of the Korotkoff sounds increases before finally 
disappearing altogether (Korotkoff phase 5) in indication that cuff pressure is now at minimal 
(i.e., diastolic) blood pressure.25 
There are a number of limitations to this method that have been increasingly implicated 
in the misdiagnosis of or the failure to diagnose HT.24 One reason for these errors is inherent 
observer bias in the form of terminal digit preference, which is the predisposition to round 
readings to a convenient last digit, such as zero.26 Additionally, age-related hearing loss has been 
shown to negatively affect auditory procedures involving the use of a stethoscope.28 Furthermore, 
both diagnosis and treatment are subject to some variation depending on minor differences in 
protocols used and experience level of the assessor.28  
Automated Oscillatory Blood Pressure Measurement 
In effort to control for observer error, use of automated devices is increasing.24 As with 
sphygmomanometric auscultation, an appropriately sized cuff is placed around the upper arm to 
measure blood pressure at the brachial artery. After initial inflation to a pressure sufficient to 
occlude the artery, the cuff begins to deflate. A microprocessor inside the cuff then measures 
moment-to-moment changes (i.e., oscillations) in pressure, and MAP is recorded at the point of 
greatest oscillation. An algorithm is then used by the microprocessor to calculate SBP and DBP 
from MAP.24, 29 Although prone to some error due to variations in algorithms designed by 
suppliers, the accuracy of the oscillometric method is improving.15 Nevertheless, equipment 
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should still be regularly calibrated against a known standard in order to ensure the validity and 
reliability of measurements, and thereby ensure the accuracy of HT assessment.3 
Despite the production of more accurate oscillometers, and the best efforts of governing 
bodies to educate practitioners in the best strategies to minimize error, clinical diagnosis and 
management of HT remain unacceptably low.30 Although a plethora of international guidelines 
exist regarding the diagnosis of HT, the following section outlines the current Canadian 
recommendations put forth by the Canadian Hypertension Education Program (CHEP) for the 
assessment of HT.31  
 1.2.2 Diagnosing Hypertension 
 Resting Clinical Blood Pressure Measurement 
When using resting clinical measurements, average pressures of >160mmHg SBP and/or 
>100mmHg DBP over 3 visits, or >140mmHg SBP and/or >90mmHg DBP over 5 visits, 
constitute a diagnosis of HT.31 For sphygmomanometric auscultation, measurements should be 
taken 3 times, discarding the first, and averaging the final two. Initial assessment should be done 
in both arms, and if one side has a higher pressure, that arm should be used in subsequent 
evaluation.31 With respect to automated oscillometric blood pressure measurements, the first 
reading taken by the automated device is discarded and remaining measurements are averaged. 
Regardless of the equipment used, there are a number of conditions that should be 
standardized. For example, as blood pressure is influenced heavily by emotional states; physical 
activity; body position; caffeine consumption; hydration status; fed states; alcohol consumption; 
bladder distension; body temperature; and diurnal rhythms,15 it is recommended that situational 
factors, such as room temperature and volume, be controlled, and that emotional states be 
recorded.15 In addition, allowing for at least 5 minutes of quiet rest prior to measurement allows 
for recovery from the effects of recent movement and should also minimize the effects of 
increased respiration on blood pressure.15, 31 There should be no talking during measurement, as 
this too can affect blood pressure.31 The CHEP further recommends having individuals in a 
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relaxed, seated position with back support.31 When seated, posture should be upright, legs 
uncrossed, with feet flat on the floor. The upper arms should be elevated to the level of the heart, 
as pressure will increase as the arms are lowered below, or decrease as they are raised above, this 
level.31 As postural hypotension is common in the elderly32 and may be related to diabetic 
neuropathy,33 supine measurements may be taken in lieu of seated measurements in these 
populations.31 Finally, upper arm cuffs should be properly sized, as those that are either too short 
or too narrow (“undercuffing”) will overestimate blood pressure, and those that are too long or 
too wide (“overcuffing”) may underestimate blood pressure, although evidence for the latter is 
weaker.15 As such, a length between 80% and 100% of arm circumference, and width near 40% 
of arm circumference is recommended.31 
Clinical measurements often misrepresent true or mean pressures throughout the day, and 
do not reflect diurnal changes and blood pressure variability.34 Of particular interest are two 
phenomena that greatly confound clinical blood pressure measurement and lead to both false 
identification and false denial of HT: 1) white-coat HT, and 2) masked HT. 
 White-coat HT is characterized by inflated resting blood pressure values in excess of 
140/90mmHg when measured clinically.15 In individuals with white-coat HT, average daily and 
nocturnal (i.e., night-time) blood pressure is actually below hypertensive values. This is not 
recognized when assessment is restricted to resting clinical measurements and can lead to a false 
positive diagnosis of HT, resulting in inappropriate treatment action. Conversely, HT that exists 
outside of the clinic only is known as masked HT,35 and such individuals may easily be 
misclassified as normotensive.15 Thus, four categories of individuals exist in clinical blood 
pressure measurement: those who are correctly identified as hypertensive; those who are 
incorrectly identified as hypertensive (i.e., white-coat hypertensives); those who are incorrectly 
identified as normotensive (i.e., masked hypertensives); and those who are correctly identified as 
normotensive.35  
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 As a partial solution to the inherent problems of resting blood pressure measurement 
techniques within a clinical setting, use of at-home, automated oscillometric devices to measure 
resting blood pressure has increased rapidly in recent years,36 as has the use of 24-hour 
ambulatory blood pressure monitors. 
 At-Home Resting Blood Pressure Measurement  
The CHEP recommends use of home blood pressure measurement in cases of 
demonstrated white-coat HT and masked HT, as well as in individuals where secondary HT is 
likely, such as in those with chronic kidney disease or diabetes mellitus,31 or in those where non-
adherence to prescribed treatment is suspected.31 When using home blood pressure measurement, 
diagnosis of HT requires that average SBP be >135mmHg, and/or that average DBP be 
>85mmHg. In cases of suspected white-coat HT, in which initial home blood pressure values are 
below 135/85mmHg despite clinical measures in the hypertensive range, a seven-day period of 
morning and evening home monitoring is required. Values from the first day are disregarded.31  
As with clinic-based measurement procedures, to ensure accuracy of measurement and 
validity of interpretation, the CHEP provides recommendations relating to equipment, training, 
and procedures for home blood pressure monitoring.31  
Home measurements are not free of bias, however, and may be influenced by the 
individual in at least two significant ways: Firstly, individuals are able to fabricate pressures 
when the device itself does not provide a print-out or send a direct report to the physician; and 
secondly, home monitoring can be anxiety-inducing in individuals who develop “an obsessional 
interest in blood pressure”.15(p839) 
 Ambulatory Blood Pressure Measurement  
Like clinical and home measurements, ambulatory blood pressure measurement (ABPM) 
involves placement of a cuff around the upper arm for assessment of blood pressure at the 
brachial artery using automated oscillometry. The cuff is attached to a portable monitor by an 
inflationary hose, and is programmed to inflate at regular intervals (e.g., every 30 or 60 minutes) 
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throughout the prescribed measurement period, usually 24 hours.15 All blood pressure values are 
recorded within the monitor and can be uploaded to a computer after completion of the test for 
assessment of HT. 
Blood pressure tends to be slightly lower when measured outside the clinic, and therefore 
the cutoff values for ambulatory HT screening are also lower. Cardiovascular risk increases at 
pressures above waking values of 135/85mmHg and average 24-hour values of 130/80mmHg,37 
although there is no clearly defined lower limit at which risk begins to increase.38 Nevertheless, 
these values correspond well to clinical measurements, and are therefore recommended by the 
CHEP for diagnosis of HT using ABPM.31 
The ability to measure over longer periods, especially overnight, is largely what sets 
ABPM apart from clinical and home resting measurements. This is true when using ABPM not 
only as a diagnostic tool for HT, but also as a prognostic tool and predictor of cardiovascular 
mortality.39 The following section highlights a small segment of the substantial literature 
documenting the usefulness of ABPM over the techniques previously described. 
Advantages of Ambulatory Blood Pressure Measurement 
ABPM using an accurate device is superior to clinical and home resting blood pressure 
measurement on many accounts. In addition to its ability to identify white-coat and masked HT, 
its use of automated, repeated measurements throughout a 24-hour period enables it to estimate 
mean blood pressure; monitor diurnal rhythms and nocturnal changes in blood pressure; and 
assess blood pressure variability.15, 34 It does so while eliminating the effects of digit preference, 
inter-rater discrepancies, and anxiety.15 In essence, it provides a truer reflection of actual blood 
pressure levels during activities of daily living and sleep.34 As mentioned above, however, its 
usefulness extends beyond simply providing a clearer picture of blood pressure behaviour. 
Numerous studies have examined the prognostic significance of ABPM over the last 30 
years,15 providing powerful evidence for its superior prediction of CVD-related mortality, as well 
as for its importance in improving management of HT and CVD.37, 38, 39, 40, 41  
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 In a direct comparison of ABPM with clinical blood pressure measurements, over 5000 
untreated hypertensive adults were followed for a median of 8.4 years. Baseline ambulatory and 
clinical pressures were examined for their associations with cardiovascular mortality. ABPM was 
shown to be a significantly better predictor of mortality than clinical measurements, with 
increases of 10mmHg SBP and 5mmHg DBP being associated with hazard outcomes for 
cardiovascular mortality in day-time, nocturnal and 24-hour ABPM.39  
 Since nocturnal blood pressure tends to be lower than daytime pressures in healthy 
individuals,15 reduction or non-existence of nocturnal dipping is suggestive of increased 
cardiovascular risk42 and target organ damage.43 Accordingly, the study described above39 
reported that nocturnal pressures were superior to daytime pressures in their predictive value for 
cardiovascular mortality. 
These associations of ABPM with cardiovascular mortality are not limited to 
uncontrolled hypertensives. In another prospective study examining the relationships of 
ambulatory and clinical measurements,38 similar relationships were found in a general population 
cohort of 1700 adults followed for over 10 years with prominent CVD risk factors, but who had 
no history of CVD. Increases of 10mmHg SBP and 5mmHg DBP were again associated with 
hazard of cardiovascular events and all-cause mortality. Importantly, however, no clinical blood 
pressure measurements were significant predictors of cardiovascular or all-cause mortality.  
These findings offer tremendous support for ABPM as a better alternative to resting 
clinical measurements.38 Nevertheless, Hansen and colleagues38 note that the relationship between 
ABPM and mortality followed a log-linear grade, preventing identification of a clear lower-limit 
for prediction of increased risk (as mentioned above). They therefore suggest that assessment of 
ambulatory blood pressure alone is insufficient for prognosis without consideration of other risk 
factors.38  
 Despite the many advantages of ABPM over clinical and home resting blood pressure 
measurements, there are a few noteworthy limitations.15 First, variance in blood pressure readings 
11 
 
has been demonstrated in validated monitors, calling the accuracy of the measurements into 
question, and suggesting the need for a standardized algorithm when estimating these values from 
MAP.44  
Secondly, ABPM is costly.15 Nevertheless, although expensive, it has been shown that 
long-term savings associated with improved healthcare and reduction of the economic burden of 
disease significantly outweigh the short-term expenditure associated with ABPM.45  
ABPM is also more intrusive and time-demanding than other available measurement 
techniques; can be uncomfortable (e.g., during sleep); and may be disruptive to activities of daily 
living.46 Naturally, then, a further complication is that individuals may reject use of an 
ambulatory monitor,15 or at least experience anxiety related to discomfort or inconvenience.  
1.3 DUAL-ARM BLOOD PRESSURE MEASUREMENT 
One of the most under-utilized recommendations in HT diagnosis in the primary care 
setting is the measurement of dual-arm blood pressure.30 Inter-arm differences (IADs) in both 
SBP (sIADs) and DBP (dIADs) have been documented in a small percentage of the population 
for over 100 years,47 yet until recently the clinical significance of these differences has been 
unclear.48, 49 In terms of HT diagnosis, most guidelines recommend that physicians conduct at 
least one blood pressure measurement in each arm (i.e., dual-arm), utilizing the higher reading as 
a diagnostic marker for HT.3, 15, 31, 50 Generally, these measurements are taken in 3 ways: 1) 
sequentially, using the same device; 2) sequentially using different devices; and 3) 
simultaneously, using separate devices. More recently, single monitors have been developed with 
the capability of measuring blood pressure in both arms, either sequentially or simultaneously. 
While these monitors would be optimal for determination of IADs, they are expensive and are 
therefore not yet in widespread use.51 
Dual-arm measurement has been recommended in nearly every set of Western guidelines 
for the diagnosis of HT published in the last 13 years.49 Although not commonly practiced in 
primary care, recent evidence has demonstrated more value to its use for its primary purpose of 
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identifying HT, and also for prognosis of cardiovascular morbidity and mortality in at least some 
populations.  
1.3.1 Recent Developments in the Clinical Implications of IADs 
Previous research had indicated that dual-arm blood pressure measurement might serve 
as a primary care screening tool for certain cardiovascular pathologies, including peripheral 
vascular disease (PVD) and subclavian stenosis (SS). PVD is characterized by stenotic occlusion 
of a large artery outside of the central vasculature, that is, that of the heart, aortic arch, or brain.52 
It is most readily identifiable by a reduced ankle-brachial pressure index (ABPI; ratio of blood 
pressure measured at the ankle to that at the brachial artery).53 PVD has been defined as an ABPI 
of <0.9, and is significantly associated with SS,54 the major cause of atherosclerotic obstruction in 
the upper limbs.55 Dual-arm measurements have been used to identify SS as a sIAD of 
>15mmHg,54, 55 and sIADs >10mmHg have been taken to indicate the presence of asymptomatic 
PVD.56  
 In what is arguably the most important study in the history of IAD research, Clark, 
Taylor, Shore, Ukoumunne, and Campbell57 present a meta-analysis of 28 studies examining the 
magnitudes of IADs and their relationships to certain arterial diseases; risk ratios (RRs), hazard 
ratios (HRs), and survival; and the effects of measurement method (i.e., simultaneous versus 
sequential) and baseline cardiovascular risk (i.e., community versus hospital cohort) on these 
relationships. Although there was no association with angiographically proven PVD, multiple 
studies demonstrated a relationship between a sIAD of >15mmHg and PVD in the leg, as 
identified by an ABPI of <0.9.58, 59 Pooled sensitivity and specificity for a sIAD of >15mmHg for 
PVD were 15% and 96%, respectively.57 When the cutoff was lowered to a sIAD of >10mmHg, 
pooled sensitivity for PVD increased to 32%. RRs for PVD identified by sIADs >10mmHg and 
>15mmHg were 2.44 and 2.48, respectively, with no significant effect of measurement method or 
baseline cardiovascular risk. Strikingly, pooled analysis revealed that angiographically proven SS 
of more than 50% typically manifests as a sIAD of approximately 35mmHg. This is a much 
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higher magnitude than the sIAD of >15mmHg used in previous studies when defining SS.54, 55 
However, smaller differences of 10 – 20mmHg  were strongly related to lesser stenosis, and the 
authors note that differences of 10 – 16mmHg  have been proposed as minimum values necessary 
for referral of an individual for angiographic testing.57, 60, 61 
No significant associations were found between sIADs of any magnitude with coronary 
artery disease (CAD), regardless of the method of blood pressure measurement. This suggests 
that the etiology of IADs is unrelated to occlusion of myocardial vasculature. However, pooled 
data from studies using sequential measurements did reveal a relationship between sIADs of 
>15mmHg and pre-existing cerebrovascular disease (CRVD), with a sensitivity of 8%, specificity 
of 93%, and a RR of 1.6. Thus, disease of at least some of the central vasculature is related to 
IADs. Interestingly, however, this association did not exist in non-invasive, simultaneous blood 
pressure measurement,57 suggesting that perhaps in some instances, sequential measurement may 
be preferable.  
With respect to survival, three studies report associations between sIADs and increased 
mortality.62, 63, 64 Because these studies examined IADs in individuals with vascular or renal 
problems62, 64 and hypertension,63 the authors of the meta-analysis57 note that only one is 
generalizable to a wider population.63 It is therefore suggested that sIADs are useful as an 
independent predictor of cardiovascular events and death in only those populations with high 
baseline cardiovascular risk, until further information is available in low-risk groups.57 
 Finally, sIADs of > 15mmHg were associated with hazard outcomes for both all-cause 
and cardiovascular mortality. In this instance, there was also weak evidence for a stronger 
relationship between all-cause mortality and sIADs when measured sequentially, rather than 
when using a simultaneous method.57 
Curiously, despite the known tendency of sequential blood pressure measurements to 
overestimate prevalence and magnitude of IADs,65 Clark and colleagues57 found no significant 
disparity in mean IADs when comparing studies that employed single, sequential measurements 
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with those using repeated, simultaneous measurements. Nevertheless, use of only a single (rather 
than repeated) sequential measurement was associated with CRVD, whereas repeated, 
simultaneous measurements were not. Thus, it may be that the tendency of single, sequential 
measurements to bolster IADs renders them more sensitive to pathologies less strongly associated 
with blood pressure discrepancy. Alternatively, as the authors suggest, these findings may be 
indicative of bias introduced in a sequential measurement protocol.57 Future studies should 
therefore continue to adopt both simultaneous and sequential methodologies, where possible, to 
further examine the nature of this relationship. 
Clark and colleagues57 conclude their meta-analysis with the suggestion that sIADs 
>10mmHg and >15mmHg may be, at the very least, useful in identifying those individuals 
requiring further assessment. Taken together, the findings of increased mortality in individuals 
with high cardiovascular risk and the association with all-cause and cardiovascular mortality in 
cases of sIADs >15mmHg, suggest strongly that a difference of this magnitude “could be a useful 
indicator of vascular disease and death.”57(p905) 
Along these lines, Clark, Taylor, Shore, and Campbell66 published the results of a 10-year 
study following a primary care cohort of 230 individuals being treated for hypertension, 183 of 
whom had no pre-existing CVD. The aim of the study was to fill a gap in the literature regarding 
survival rates in individuals with IADs over a 10-year period, as well as to provide data on the 
implications of IADs for individuals with no history of CVD. HRs for cardiovascular events, 
cardiovascular mortality, and all-cause mortality were calculated for those with no pre-existing 
CVD, as well as for all participants in a full-case analysis. In addition, participants’ risk of 
combined fatal and non-fatal events was stratified on the bases of the magnitude of their sIAD 
and Framingham Risk Score (FRS).67  
To identify IADs, the investigators66 used pairs of sequential blood pressure readings, 
repeated on two more occasions to verify their permanence. Thresholds of 10mmHg and 
15mmHg were used in identifying sIADs. dIADs were identified as discrepancies of 10mmHg or 
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more only. At baseline, mean sIADs of >10mmHg and >15mmHg were found in 24% and 9% of 
participants, respectively, while 6% showed mean dIADs >10mmHg. At 10-year follow-up in the 
full-case analysis, sIADs equal to, or exceeding both thresholds of 10mmHg and 15mmHg were 
associated with increases in all risk categories (i.e., cardiovascular events, cardiovascular 
mortality, and all-cause mortality). Furthermore, for each increase in sIAD magnitude of 1mmHg, 
hazard outcomes increased by between 5 and 6%. In similar fashion, dIADs showed a lesser 
relationship with heightened hazard of cardiovascular events and combined non-fatal events or 
all-cause mortality, with a 9% increase for fatal and non-fatal events with each increase in 
magnitude of 1mmHg.66 The implications of these findings become clearer when risk is stratified 
by combining IAD prevalence with the FRS in non-CVD individuals. When considered in 
conjunction with FRS estimates exceeding 20%, sIADs of >10mmHg were indicative of 
increased combined fatal and non-fatal events, demonstrating predictive accuracy greater than 
that yielded by the FRS alone.66 Crucially, then, this study represents the first 10-year 
longitudinal evidence for the prognostic value of IADs, not only for people with CVD, but also 
for hypertensives with no pre-existing CVD. 
This collective work characterizes the most meaningful data to-date. The meta-analysis 
described above57 represents the first comprehensive synthesis of IADs’ relationships to PVD, 
SS, and CRVD, and suggests the usefulness of dual-arm measurement in risk stratification for 
individuals at high cardiovascular risk. Furthermore, it lends support to the earlier proposition 
that sIADs >10mmHg and >15mmHg are useful in the identification of individuals in need of 
angiographic assessment for SS.60, 61  In turn, the longitudinal study following a cohort of 
hypertensive CVD and non-CVD individuals66  substantiates previous evidence62, 63, 64 for the 
ability of both sIADs and dIADs to assess cardiovascular risk. The capacity for combined 
evaluation of FRS and sIADs to stratify risk is a powerful argument for the necessity of dual-arm 
blood pressure  measurement as an adjunct to risk factor-based stratification in non-CVD 
hypertensives. 
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As stated earlier, this more recent evidence has prompted increased discussion regarding 
the usefulness of dual-arm blood pressure measurement in clinical settings.30, 68, 69, 70, 71 If resting 
dual-arm blood pressure measurement is a relatively easy technique47 that has the potential to 
save lives by improving diagnosis and allowing clinicians to make better treatment decisions,72 
then why is there any resistance at all to its adoption in primary care? Although the findings from 
recent years are indeed persuasive, a number of noteworthy objections have been raised.69, 71 
Therefore, proper treatment of the subject of the diagnostic and prognostic value of IADs, as well 
as the practicality of the measurement, requires that these objections be addressed. 
1.3.2 Limitations and Challenges to Recent Evidence 
 One of the most significant challenges to the meta-analysis presented by Clark and 
colleagues57 is the issue of the low sensitivities and high specificities of IADs for PVD and 
CRVD.69 Sensitivity refers to the ability of a test to correctly identify a positive result.73 
Therefore, in the case of the 32% specificity of sIADs >10mmHg for PVD, sIADs of this 
magnitude will only be found one-third of the time when PVD is present.  It has therefore been 
argued that the low sensitivity values of IADs for PVD and CRVD indicate the poor ability of 
dual-arm blood pressure measurement to positively identify these conditions.69, 71 This is indeed a 
strong argument against dual-arm measurement as a sole diagnostic tool. It is not, however, an 
argument against the value of manifest IADs in diagnosis. 
 Recall that meta-analysis revealed that sIADs >15mmHg had specificities of 96% for 
PVD and 93% for CRVD.57 Specificity refers to the ability of a test to correctly identify a 
negative result, such that in the absence of PVD, a sIAD >15mmHg will also be absent 96% of 
the time.73 However, in the presence of a sIAD at or above this threshold (i.e., a positive result), 
the IAD indicates the presence of disease very strongly.74 Thus, while the likelihood of finding an 
IAD exceeding these values is relatively low when PVD or CRVD are present (i.e., due to low 
sensitivity), in the event that such a difference is found, the probability of correct diagnosis is 
very high (i.e., due to high specificity). In simpler terms, the ability of dual-arm measurement to 
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rule out PVD or CRVD is relatively low, since IADs are not always concomitant with these 
diseases. However, the ability of dual-arm measurements to rule them in is very high when an 
IAD is found.74 
 Consider also that manifestations of sIADs >10mmHg and >15mmHg, and dIADs 
>10mmHg, are all associated with increased hazard outcomes for cardiovascular events in 
hypertensive individuals.66 Since hypertensives already undergo factor-based cardiovascular risk 
stratification,67 dual-arm blood pressure measurement would be a simple method of improving 
accuracy, and would also identify at least some of those for whom further vascular assessment is 
appropriate.57, 66 Therefore, assuming the validity of the survival data in Clark and colleagues’ 
cohort study,66 the assertion that dual-arm measurement is a poor screening test69 is only correct if 
such measurement is applied in the absence of other considerations. In fact, however, Kim does 
challenge the validity of these findings on numerous accounts69. 
 Citing a recent meta-analysis of IADs and measurement methods,65 Kim69 criticizes Clark 
and colleagues’ blood pressure data collection protocol66 for two reasons. First, repeated, 
simultaneous measurements are the ideal way of assessing discrepancy between arms,65 yet in this 
cohort study, paired sequential measurements were used instead.  Secondly, Kim notes that if 
some participants had highly variable blood pressure, IADs may have been overestimated by the 
use of repeated measurements on separate days.69 Given that high variability in blood pressure is 
associated with cardiovascular events, it is possible that this association was mistaken for a 
relationship between IADs and cardiovascular risk.69 
 Although these are important considerations, the first is already dealt with post-hoc in 
Clark and colleagues’ study.66 Samples of the cohort were examined after the fact with 
simultaneous measurements, demonstrating similar prevalence of both sIADs and dIADs 
>10mmHg when compared with their sequential findings. Furthermore, when other controls are 
in place, careful sequential measurement is robust to serious inflation of IAD prevalence and 
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magnitude.75 Likewise, the subgroup evaluation of measurement method in Clark and colleagues’ 
meta-analysis57 showed little effect on mean IAD values. 
 As for the potential confounding effects of high blood pressure variability,69 Kim’s point 
is well taken. However, this author finds the apparent consistency of the IADs to be supportive, 
rather than destructive, to the validity of repeating measurements over multiple days. High 
variability in blood pressure might suggest that these IADs should be inconsistent at second and 
third measurements. The fact that the authors were able to detect and report IADs despite these 
potential variations should therefore be interpreted as a strength of their prevalence data, rather 
than as a weakness. 
 Kim offers further objections based on the use of crude categories of risk factors for 
calculation of the FRS; confounding effects of various drugs on the strength of associations 
between IADs and cardiovascular risk; and the modest size of the sample.69 These are noteworthy 
limitations, and lead Kim to declare the inconclusiveness of the prognostic value of IADs69. 
Nevertheless, although Clark and colleagues’ findings66 are not definitive, when considered in 
conjunction with the association of IADs with PVD, CRVD, and SS,57 it seems likely that these 
results are at least accurate to the degree that they should be considered seriously.  
To this point, Kim does acknowledge the high predictive value of sIADs of >10mmHg 
for upper-limb PVD, especially in the presence of CVD risk factors69. Therefore, though skeptical 
of some evidence for the prognostic value of IADs, he acknowledges their potential value and 
concludes by underscoring the need for further examination of how an IAD compares to “markers 
of subclinical atherosclerosis, biomarkers, and clinical predictors as a predictor of mortality from 
cardiovascular causes.”69(p2034)  
Interestingly, several very recent publications have examined associations with just such 
markers of atherosclerosis and cardiovascular risk.76, 77, 78, 79, 80, 81  Although extensive discussion 
of these latter findings is beyond the scope of this review, a short overview of the findings will 
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suffice to demonstrate the mounting evidence to support IADs as a predictor of cardiovascular 
mortality.  
Briefly then, in this latest research, sIADs of >10mmHg were associated with 
albuminuria in individuals with type II diabetes, a marker of both diabetic nephropathy and 
CVD.76 sIADs and dIADs of >10mmHg were associated with heightened mortality from 
cardiovascular and all causes, as well as PVD in individuals with acute ischemic stroke.77 Further 
investigation into the relationship of IADs to stroke occurrence revealed that magnetic resonance 
imaging evidence of a past infarct was twice as common in individuals with sIADs >15mmHg 
than in those without.78 Additionally, increased carotid-femoral pulse wave velocity was 
significantly associated with sIADs >10mmHg, suggesting that increased arterial stiffness may 
account in part for the increased mortality observed in individuals with an IAD.79 
Finally, sIADs of >15mmHg were associated with elevated C - reactive protein, a by-
product of inflammation and marker of cardiovascular risk.80, 81 IADs were not associated with 
cerebral, coronary, or aortic atherosclerosis,77 or other biochemical cardiovascular markers or risk 
factors,80, 81 suggesting the need for further research into these very specific relationships between 
IADs and peripheral and subclavian atherosclerosis. In any case, this recent work represents a 
growing body of literature that supports the value of IADs as both an independent and adjunct 
predictor of cardiovascular risk in individuals with other risk factors. 
Despite this increasing evidence however, it cannot be overlooked that the current debate 
surrounding the relevance of dual-arm blood pressure measurement to these various diseases and 
hazard outcomes is somewhat misleading in terms of the relevance of this technique to clinical 
practice.  At its most basic level, blood pressure measurement is used in clinical settings to screen 
for the presence of hypertension. In examining the value of measuring blood pressure in both 
arms, therefore, the most obvious and immediate question should be whether this procedure is 
capable of identifying HT that manifests in one arm and not the other. In fact, this is the chief 
purpose of dual-arm blood pressure measurement in primary care.31, 82, 83  
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In light of the previous discussion of the current suboptimal control of hypertension, the 
mere fact that dual-arm blood pressure measurement might help to identify hypertension should 
be more than enough reason to use it in primary care.72 As powerful evidence for this contention, 
Agarwal recently found that use of only one arm in blood pressure measurement could have 
missed uncontrolled hypertension in 26% of participating individuals.84 Thus, regardless of the 
diagnostic and prognostic relevance for other diseases and risk factors, dual-arm blood pressure 
measurement in primary care is imperative if control of hypertension is to improve. 
1.3.3 Practical Problems with Dual-Arm Blood Pressure Measurement 
According to the awareness-to-adherence model of the steps to clinical guideline 
compliance,85 both knowledge and acceptance of a guideline are necessary precedents to its 
adoption. In a British survey of practitioner compliance with HT guidelines, physicians expressed 
high awareness of, but little agreement with, the recommendation for dual-arm blood pressure 
measurement.86 In other words, physicians doubt the efficacy of dual-arm measurements to yield 
the desired outcome.87  
In response to these findings, it was noted that, of all major HT guidelines from the UK, 
Europe, Canada, United States, Australia, New Zealand, Japan, and South Africa published 
between 1977 and 2009, only one publication provided a justified, referenced rationale for the 
procedure.88 This is understandable however, as the true value of dual-arm blood pressure 
measurement is only recently coming to light.  The lack of justification presented for this 
directive may therefore help to explain the disjunction between recommendation and practice, 
and it is likely that inclusion of a solid rationale will increase adherence.88 Recent findings will 
likely contribute to this increase, and should be presented in future guidelines.  
Nevertheless, amongst physicians who do express agreement with the directive to 
measure blood pressure in both arms, adherence is still low.86 In terms of adherence to guidelines, 
clinicians’ behaviour is heavily influenced by environmental factors.85, 87 Specifically, time-, 
personnel-, and resource-related constraints have a large influence on guideline compliance. 
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Proper blood pressure measurement, even when taken only in a single-arm, is time-consuming. 
As explained, at least 5 minutes of undisturbed rest are required prior to obtaining the first 
measurement.89 Dual-arm measurements demand slightly more time, as well as resources 
(depending on the protocol used, as noted above), rendering such measurements impractical in a 
busy clinic.  
Current CHEP recommendations take a blanket approach to the application of dual-arm 
measurement techniques.31 Identifying the population(s) for whom they have both diagnostic and 
prognostic value may therefore provide a viable option for increasing physicians’ compliance to 
dual-arm measurement guidelines, by allowing for removal of recommendations for those to 
whom they have little or no value. A population that demonstrates a low or non-existent 
prevalence of IADs may present such an opportunity. To address the issues of the efficacy and 
relevance of dual-arm blood pressure measurement in non-CVD adults, the following section 
examines gaps in current literature. 
1.3.4 Gaps in Current Dual-Arm Blood Pressure Measurement Literature 
At present, both the prevalence and clinical implications of IADs in young, 
normotensive, apparently healthy adults are unclear. Numerous studies have examined IADs in 
young adults,90, 91, 92, 93, 94, 95 demonstrating a high degree of variability in their results (e.g., 
between 3%94 and 83%90 prevalence of sIADs >10mmHg). Complicating interpretation of these 
results are a number of methodological weaknesses. More specifically, most previous 
investigations are limited by one or more of: inclusion of participants with acutely presenting 
health complications;90, 91, 95 inclusion of unilaterally wounded individuals;90, 91 lack of same-day 
repeat measurements in accordance with published guidelines (i.e. use of only a single 
measurement);92 use of sequential bilateral measurements only (i.e. no  simultaneous bilateral 
measurement whatsoever;90, 91, 92, 95 broad age ranges in studies examining prevalence in the 
general population;94 use of multiple raters;90, 91, 92, 93 and use of only a single IAD threshold when 
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calculating prevalence,92, 95 despite the lack of a known, clinically relevant threshold in this 
population.  
It has been suggested that one or more of these limitations has the tendency to 
overestimate prevalence of IADs. Momentary changes in whole-body blood pressure due to 
white-coat or other effects may cause a different reading in the contralateral arm when measured 
subsequent (i.e., sequential measurements) to completion of measurement in the first arm.92, 96 
Similarly, inter-rater discrepancies might cause an increase in frequency of IADs detected when 
using an auscultatory method. 
Recently, Grossman and colleagues97 addressed the question of IAD prevalence in a 
retrospective analysis of data collected from 877 Israeli Air Force recruits. They found that sIADs 
>10mmHg were present in 12.6% of participants. IADs were not correlated with body mass index 
(BMI), heart rate, age, sex, or first arm measured. Although this large-scale study did address 
some of the aforementioned methodological problems, it still bears a few important limitations.  
First, blood pressure was taken sequentially. Although sequential measurements more 
accurately reflect the actuality of clinical practice,97 to approach the question from only this 
perspective unfortunately adds little to the current understanding of how many individuals within 
this population have a physiologically meaningful IAD. Second, although same-day repeat 
measurements were used, they were only repeated once, yielding two systolic and two diastolic 
measurements per arm. If a sequential protocol does indeed suffer from the effects of white-coat 
hypertension, as Martin and colleagues have suggested,96 then two measurements per arm may 
not be enough to attenuate these effects. Third, since the study was retrospective, the original 
raters may not have intended for the results to be used in scientific analysis. Although a good deal 
of information was documented with regards to rater identity and side of the first arm measured, 
it is unclear whether participants were instructed to remain still and silent throughout all 
measurements; whether the assessors spoke to the participants throughout measurements; what 
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the environmental conditions were like; or whether the assessment adhered to standard laboratory 
conditions (e.g., as regards fed states, hydration, recent activity and alcohol consumption). 
Fourth, and perhaps most importantly, there was no repeat testing on a second day to test 
reliability and confirm the permanence of IADs in this population. Over 80 years ago, Korns and 
Guinard suggested that IADs in this population are transient and have little physiological 
significance.92 Grossman and colleagues note that atherosclerotic obstruction is an unlikely cause 
of IADs in these individuals and similarly state that their etiology and prognostic significance are 
thus unclear.97 Other studies have had conflicting results surrounding the question of the 
permanence of IADs,64, 75 and to this author’s knowledge, no prospective study has yet addressed 
this question in young, healthy adults. Given the lack of simultaneous measurement and the 
retrospective nature of the study, it is possible that Grossman and colleagues97 could have 
overestimated the prevalence of true IADs, a question that repeat measurements on a second day 
would have helped to answer. 
Also of interest is the relative absence of literature regarding dual-arm ABPM.44 Of the 
three studies that have looked at different readings from simultaneously worn ambulatory 
monitors, two have used different monitor models for assessment of inter-model reliability.44, 98 
The other study examined mean differences between right and left arms for the purpose of 
determining which arm should be used in ABPM.46 Although the results demonstrated higher 
readings in the dominant arm, suggesting that this is how ABPM should be taken, the sample was 
very small (n=10), and was made up of individuals who already had pre-determined sIADs of 
>10mmHg. Therefore, little data exist concerning the ability of ABPM to identify IADs. Given 
the substantial evidence for ABPM as a better alternative to resting, clinical measurements, as 
well as the diagnostic and prognostic importance of IADs, the question of the value of dual-arm 
ambulatory measurements in clinical practice is key. 
In summary, there is a need for research examining the prevalence and reliability of IADs 
>5, 10, 15, and 20mmHg across multiple days in young, healthy adults. Current guidelines 
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provide the same recommendation regarding application of dual-arm blood pressure measurement 
protocols across all age groups. However, the prevalence and reliability of blood pressure IADs in 
young, healthy adults are not well understood, and therefore their clinical relevance is unknown. 
Additionally, there is minimal research examining ABPM taken in both arms, and no study has 
directly investigated the feasibility of dual-arm ABPM for assessment of IADs in any population. 
1.4 OBJECTIVES 
1.4.1 Purposes and Hypotheses 
To address these gaps in the literature, this study aimed to provide data that will lay a 
foundation for future, large-scale studies investigating the prevalence and second-visit reliability 
of IADs in young, healthy adults. Furthermore, as a first step in characterizing IADs in ABPM, it 
explored the feasibility of a sequential ABPM protocol for identifying IADs in this population 
during activities of daily living. 
Specifically, it was hypothesized that: in young, normotensive, apparently healthy adults 
subject to a well-controlled protocol: 1) there would be no reliable IAD in resting blood pressure 
(defined as IADs >5, 10, 15, and 20mmHg)8, 14 detected when measured sequentially or 
simultaneously; and 2) there would be no reliable IAD in ambulatory blood pressure (defined as 
IADs >5, 10, 15, and 20mmHg)8, 14 when measured sequentially. The results of this study have 
important implications for the understanding of IADs and their clinical implications in this 
population. 
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2.1 Introduction 
Hypertension (HT), a condition characterized in adults under 60 years of age as sustained 
elevations in resting systolic blood pressure (SBP) above 139mmHg, and/or in resting diastolic 
blood pressure (DBP) above 89mmHg,1 measured at the brachial artery, afflicts greater than 1 
billion people worldwide.2 It has been identified as one of the most preventable causes of  
cardiovascular disease (CVD) and related mortality,3, 4, 5 being responsible for 9.4 million deaths 
each year.2 In 2013, the World Health Organization deemed HT a global health crisis, 
highlighting its prevention as a cornerstone in the effort to reduce death from non-communicable 
diseases.2 Accurate screening for the presence of HT in primary care settings is therefore of the 
utmost importance. 
Of particular interest for HT screening is the nearly ubiquitous recommendation for dual-
arm brachial blood pressure measurements, not only as a strategy for ensuring diagnostic 
reliability, but also for detecting the presence of certain arterial diseases.4, 7, 8, 9 Inter-arm 
differences (IADs) in both SBP (sIADs) and DBP (dIADs) have been documented in a small 
percentage of the population for over 100 years,10 yet until recently the clinical significance of 
these differences has been unclear.11, 12 In terms of HT diagnosis, it is currently recommended that 
physicians conduct at least one blood pressure measurement in each arm (i.e., dual-arm), utilizing 
the higher reading as a diagnostic marker for HT.4, 7, 8 Generally, these measurements are taken in 
3 ways: 1) they are taken sequentially, using the same device; 2) they are taken sequentially using 
different devices; and 3) they are taken simultaneously, using separate devices. It should be 
noted, however, that sequential measurements can nearly double the detected prevalence of 
IADs,13 a phenomenon possibly attributable to white-coat effects (i.e., overestimation of resting 
blood pressure due to nervousness or anxiety) in the first arm measured.14 
Expanding upon this, a recent meta-analysis now links IADs in blood pressure with an 
increased likelihood of the presence of CVD. Specifically, sIADs of at least 15mmHg are 
associated with heightened risk of asymptomatic peripheral vascular disease (PVD), and, to a 
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lesser extent, with cerebrovascular disease (CRVD) and mortality.9 In addition, angiographically 
proven subclavian stenosis (SS) of more than 50% typically manifests as a sIAD of > 35mmHg. 
Smaller differences of 10 – 20 mmHg have a high degree of specificity for lesser stenosis.9 
Interestingly, however, IADs have also been found in a study of 209 men and 155 women aged 
28-89 years with no history of CVD, with magnitudes ranging from 15 to 19mmHg SBP and 17 
to 20mmHg DBP.15  
Given the values implicated in these studies, there is a need for research examining the 
prevalence and clinical implications of sIADs and dIADs exceeding thresholds of 10, 15, and 
20mmHg in subjects with no known history of CVD to provide further insights into this 
phenomenon. Additionally, although IADs of <10mmHg are relatively common in the general 
population15 and are not usually examined, the relationship of age to the development of IADs is 
not well understood. Therefore, examination of the prevalence of IADs exceeding smaller 
thresholds (e.g., 5mmHg) and their relationships with age in younger, healthy adults is also 
warranted. Finally, no valid data exist regarding the reliability of IADs over multiple days in this 
population and thus, there is also a need for well-controlled investigations of second-day 
reliability. 
The new evidence presented for the value of dual-arm blood pressure measurement has 
prompted increased discussion as to its necessity in clinical settings.16, 17 Despite this growing 
evidence, however, implementation of dual-arm blood pressure measurement in clinical settings 
remains minimal. In 2007, Heneghen and colleagues18 found that only 13% of general 
practitioners in Britain adhered to the guideline to measure blood pressure in both arms.18 
Although the physician’s discretion is always paramount, this consistent discrepancy between 
recommendation and practice warrants investigation.  
According to the awareness-to-adherence model of the steps to clinical guideline 
compliance,19 both knowledge and acceptance of a guideline are necessary precedents to its 
adoption. In the above-mentioned study of Heneghan et al.,18 physicians expressed high 
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awareness of, but little agreement with, the recommendation for dual-arm blood pressure 
measurement.18 In other words, physicians doubt the efficacy of dual-arm measurements to yield 
the desired outcome.20  
In response to these findings, it was noted12 that, of all major HT guidelines from the 
United Kingdom (UK), Europe, Canada, United States, Australia, New Zealand, Japan, and South 
Africa published between 1977 and 2009, only one publication (European Society of 
Hypertension guidelines from 2003)7 provided a justified, referenced rationale for the dual-arm 
measurement procedure.12 The lack of justification for this directive may therefore help to explain 
the disjunction between recommendation and practice, and it is likely that inclusion of a solid 
rationale will increase adherence.21 The recent findings9 of an association of sIADs with PVD, 
CRVD and SS, highlighted above, will likely contribute to this increase, and should be 
highlighted in future guidelines. Nevertheless, amongst physicians who do express agreement 
with the directive to measure blood pressure in both arms, adherence is still low (i.e., ~13% ).18 
Thus, the question remains: if a relatively simple procedure9 has the potential to yield useful 
diagnostic information that exceeds the usefulness of traditional measurements, why is it not 
more frequently utilized?     
The simple answer to this is that clinicians’ practical application is heavily influenced by 
environmental factors, such as time-, personnel-, and resource-related expenses associated with 
dual arm guideline compliance.19, 20 Proper blood pressure measurement, even when taken only in 
a single-arm, is time-consuming. Typically, at least 5 minutes of undisturbed rest are required 
prior to obtaining the first measurement.22 Dual-arm measurements demand slightly more time 
(e.g. another measure is taken in the contralateral arm immediately following the first measure), 
as well as resources (depending on the protocol used, as noted above), rendering such 
measurements impractical in a busy clinic.  
Current guidelines take a blanket approach for all age groups to the application of dual-
arm measurement protocols.4, 7, 8 Identifying the population(s) for whom dual-arm measurement 
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has both diagnostic and prognostic value may therefore provide a viable option for increasing 
physicians’ compliance to dual-arm blood pressure measurement guidelines, by allowing for 
removal of recommendations for those to whom it has little or no value. A population that 
demonstrates a low or non-existent prevalence of IADs may present such an opportunity. 
At present, both the prevalence and clinical implications of IADs in young, 
normotensive, apparently healthy adults are unclear. Numerous studies have examined IADs in 
young adults,23, 24, 25, 26, 27, 28 demonstrating a high degree of variability in their results (e.g., 
between 3%27 and 83%23 prevalence of sIADs >10mmHg). Complicating interpretation of these 
results are a number of methodological weaknesses. More specifically, most previous 
investigations are limited by one or more of: inclusion of participants with acutely presenting 
health complications;23, 24, 28 inclusion of unilaterally wounded individuals;23, 24 lack of same-day 
repeat measurements in accordance with published guidelines (i.e. use of only a single 
measurement);25 use of sequential bilateral measurements only (i.e. no  simultaneous bilateral 
measurement;23, 24, 25, 28 broad age ranges in studies examining prevalence in the general 
population;26 use of multiple raters;23, 24, 25, 29 and use of only a single IAD threshold when 
calculating prevalence,25, 28 despite the lack of a known, clinically relevant threshold in young, 
healthy adults . It has been suggested that one or more of these limitations has the tendency to 
overestimate prevalence of IADs. As mentioned previously, momentary changes in blood 
pressure due to white-coat effects may cause a different reading in the contralateral arm when 
measured subsequent to completion of measurement in the first arm (i.e., sequential 
measurements).14, 25 Similarly, inter-rater discrepancies might cause an increase in frequency of 
IADs detected. Such limitations have prevented inclusion of these studies from a rigorous 
systematic review,10 demonstrating the need for more reliable and valid data in this population. 
More recently, Grossman and colleagues29 observed prevalence values of 13% (sIADs) 
and 9% (dIADs) >10mmHg in a sample of 877 young, healthy Israeli Air Force recruits 
undergoing routine medical evaluation (age: 26+10 years). Although this study had a large 
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sample size and did examine same-day reliability of IADs, it has some noteworthy limitations, 
including: use of a predominantly male sample (n=71 women); use of sequential measurements 
only; use of only two measurements to assess same-day reliability; the retrospective nature of the 
analysis; and the lack of repeat testing on a second day to assess the reliability of IADs over 
multiple days. Therefore, understanding of IADs in young, healthy adults remains relatively 
unchanged despite recent work.  
Also of interest is the trend over the last 30 years toward the use of ambulatory blood 
pressure measurement (ABPM),30 in which participants wear an automated, portable arm monitor 
that measures blood pressure at regular intervals during activities of daily living. As the current 
gold standard of clinical care, ambulatory measurement provides a truer reflection of a 
participant’s blood pressure.30 In fact, recent evidence suggests that ambulatory blood pressure is 
a better predictor of CVD risk than resting blood pressure measurements, and may improve 
opportunity for CVD prevention.21, 30 Currently, however, there is a paucity of literature regarding 
dual-arm ABPM.31   
Given the substantial evidence for ABPM as a better alternative to single-arm, resting, 
clinical measurements,31 as well as the diagnostic and prognostic importance of IADs, the value 
of dual-arm ABPM in clinical practice merits investigation. However, of the three studies that 
have looked at different readings from simultaneously worn ambulatory blood pressure  
monitors,31, 32, 33 two have used different monitor models for assessment of inter-model 
reliability.31, 32 The first demonstrated a bias introduced by monitor model when ambulatory 
monitors were compared with auscultatory readings in a sample of 17 normotensive and 28 
hypertensive participants.31 The second found similar mean arterial pressure (MAP; weighted 
average of SBP and DBP, such that MAP ≈ 1/3(SBP) + 2/3(DBP)) between devices in 24 healthy 
individuals (11 women, 13 men; average age 38 years old), but due to differences in algorithms 
used, systolic and diastolic estimates from MAP differed by an average of 10mmHg and 3mmHg, 
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respectively.32 Such differences indicate that data from different monitor models are not useful 
for assessing ambulatory IADs. 
The only study examining dual-arm ABPM using the same monitor model (Tycos Quiet-
Trak, Tycos-Welch-Allyn, Arden, North Carolina, USA) investigated mean 24-hour, 
simultaneous IADs in 10 participants (6 men, 4 women; average age 45+17 years) for the purpose 
of determining which arm should be used in ABPM.33 Although the results demonstrated higher 
readings in the dominant arm (145/84mmHg compared to 139/81mmHg), the sample was very 
small and consisted of individuals with HT. Therefore, little data exist concerning the ability of 
ABPM to identify IADs in other populations, and no such data exist for young, healthy adults. 
One obstacle to the assessment of IADs in this manner is the activity inherent to the 
ABPM procedure. Despite keeping arms stationary during measurement, it seems possible that 
recent activity may produce differential pressures between the arms, and thereby exaggerate the 
frequency and magnitude of detected IADs. Nevertheless, if a dual-arm ABPM protocol is shown 
to produce a valid estimation of IADs, the prognostic significance may exceed that of resting 
single- or dual-arm measurements alone. Various protocols should thus be explored in order to 
determine whether any method is capable of accurately determining the presence of IADs using 
ABPM. A population in whom low prevalence and magnitude of IADs is expected (e.g., young, 
healthy adults) might provide the ideal sample for testing the feasibility of a dual-arm ABPM 
protocol, as overestimation may be more easily identifiable. 
In summary, there is a need for research examining the prevalence of blood pressure 
IADs >5, 10, 15, and 20mmHg and their reliability across multiple days in young, healthy adults. 
Current guidelines provide the same recommendation regarding application of dual-arm blood 
pressure measurement protocols across all age groups. However, the prevalence and reliability of 
blood pressure IADs in young, healthy adults are not well understood, and therefore their clinical 
relevance is unknown. Additionally, no study has directly investigated the feasibility of dual-arm 
ABPM for assessment of IADs in any population. 
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2.1.1 Purpose and Hypotheses 
To address these gaps in the literature, the purpose of the current study was to investigate 
the prevalence and reliability of IADs in young, healthy adults. Furthermore, as a first step in 
characterizing IADs in ABPM, it explored the feasibility of a sequential ABPM protocol (the 
most cost-effective protocol for clinical practice as it employs a single ABPM device) for 
identifying IADs in this population during activities of daily living. 
It was hypothesized that: in young, normotensive, apparently healthy adults subject to a 
more controlled protocol: 1) there would be no reliable IAD in resting systolic or diastolic blood 
pressure (defined as IADs >5, 10, 15, and 20mmHg)9, 15 detected when measured sequentially or 
simultaneously; and 2) there would be no reliable IAD in ambulatory systolic and diastolic blood 
pressure (defined as IADs >5, 10, 15, and 20mmHg)9, 15 when measured sequentially. 
2.2 METHODS  
2.2.1 Study Participants 
Potential participants (healthy adults aged 18-40 years old) were invited to meet with 
study investigators in the Physical Activity and Cardiovascular Research Laboratory (HK 240, 
Department of Kinesiology, University of Windsor), where all aspects of the study were 
explained. Those still interested then provided written consent to participate (Appendix A). This 
study was cleared by the University of Windsor Research Ethics Board (REB #13-063; Appendix 
B). 
2.2.2 Eligibility  
In order to determine eligibility, participants first completed a medical questionnaire 
(Appendix C). If no medical conditions or medications were identified by the medical 
questionnaire, participants then had their resting blood pressure measured (with the unit 
designated for right-arm testing, as described below) 4 times in 2-minute intervals, following 10 
minutes of seated rest (Dinamap Carescape v100, Critikon, Tampa, Florida, USA; Appendix D). 
The first measurement was discarded as per published guidelines34 and the remaining 3 values 
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were averaged.35 Exclusion criteria were: resting single-arm blood pressure (either SBP or DBP) 
greater than, or equal to, 140/90mmHg; any overt disease or acutely presenting condition known 
to affect blood pressure; or taking prescription or over-the-counter medications known or 
suspected to affect blood pressure.  
Following completion of the informed consent and initial screening process, participants 
returned on a second day for a final test of eligibility and familiarization. Single-arm blood 
pressure was again measured as previously described. If averaged resting blood pressure values 
from the first and second visits were below 140/90mmHg, participants were deemed eligible for 
testing. Those eligible were then familiarized with study procedures. Using published values of 
the prevalence of sIADs in young persons, which have demonstrated a wide range (3%27 to 
83%23), a minimum sample of 18 participants (α = 0.05, β = 0.2, GPower 3.1.5) provided 
sufficient power.  Mean baseline characteristics of all participants are presented in Table 1. 
 
 
Table 1. Mean Baseline Characteristics of Eligible Participants; N = 18  
Characteristic  
Women (n) 2 (11%) 
Age (years) 
BMI 
25 + 4 
25.27 +4.52 
Eligibility Resting SBP 113 + 9 
Eligibility Resting DBP 61 + 7 
Note: Values are mean + standard deviation (SD); SBP = Systolic blood pressure; DBP = 
Diastolic blood pressure 
 
 
2.2.3 Study Design 
All data were collected on 2 days separated by at least 24 hours, each employing identical 
procedures to test for between-day reliability. All in-laboratory testing began in the morning, and 
was conducted in a quiet, temperature-controlled room (~21OC). Repeat testing was conducted at 
the same time of day (to within 3 hours of the initial starting time) to account for circadian 
fluctuations30 in blood pressure. Participants were asked to abstain from caffeine, alcohol, and 
vigorous exercise for 12 hours prior, and all data was collected 4 hours post-prandial. 
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In order to ensure that dual-arm resting IADs were not skewed by the oscillometers, 
resting monitors were calibrated according to manufacturer instructions to within 1mmHg of the 
same, known standard, using a digital manometer (Digital Manometer 840081, Sper Scientific, 
Scottsdale, Arizona; Appendix D). Furthermore, monitors were designated “right” and “left”, 
always being used to measure the same arm on all participants across all testing days, to allow for 
statistical comparison as a secondary method of protection against monitor bias. All testing was 
conducted by the same investigator to remove inter-rater effects from IAD outcomes. The same 
APBM monitor was used on all participants for all procedures. 
2.2.4 Testing Procedure 
Data were collected over a 2-hour timespan on each Testing Day. Blood pressure was 
measured in both arms, first while resting, and then while ambulatory. Resting measures were 
taken using both sequential and simultaneous methods, while ambulatory measures were 
sequential only. The order of testing (i.e., whether sequential or simultaneous measurement 
occurred first) was randomized and was identical on both testing days.  
Testing Days 1 and 2 
Upon arrival in the lab, participants were reminded of the testing procedures and of their 
ability to withdraw from the study at any time. Compliance with the request to abstain from 
caffeine, alcohol, vigorous exercise and food prior to testing was noted and standardized for both 
testing days. Participants were then asked to void their bladders prior to testing.35 
After voiding, participants completed the State-Trait Anxiety Inventory-Y (STAI-Y) to 
control for the effects of anxiety on blood pressure. Participants were then seated at a table and 
fitted with an appropriately-sized brachial blood pressure cuff on both right and left arms.7 Arms 
were raised to the level of the heart, and participants were seated in a stable, backed chair, with 
feet flat on the floor.34 Following 10 minutes of quiet rest, inflation of 1 (sequential) or both 
(simultaneous) of the cuffs began, depending on the order previously determined. A 10-minute 
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rest period also separated sequential and simultaneous protocols to allow for a return to baseline. 
Sequential and simultaneous measurement procedures were as follows: 
Sequential Resting Blood Pressure Measurement 
Inflation of the right brachial cuff to a value above SBP began after completion of a 10-
minute rest period, and blood pressure was measured (Dinamap Brachial Artery Oscillometer, 
Dinamap Carescape v100, Critikon, Tampa, Florida, USA; Appendix D). Precisely 1 minute 
following the initiation of the right-arm measurement, the second cuff began to inflate, measuring 
blood pressure in the left arm. Each cuff deflated and re-inflated 3 more times automatically in 2-
minute intervals, yielding a total of 4 measurements per arm. The first measurement was 
discarded34 and the final 3 measurements35 from each arm were averaged, providing 1 systolic 
and 1 diastolic mean value for each arm. 
Simultaneous Resting Blood Pressure Measurement 
Inflation of both right and left brachial cuffs began simultaneously after completion of a 
10-minute rest period, and blood pressure was measured 4 times in 2-minute intervals, again 
yielding a total of 4 measurements per arm (Dinamap Brachial Artery Oscillometer, Dinamap 
Carescape v100, Critikon, Tampa, Florida, USA; Appendix D). As with the sequential 
measurements, the first measurement was discarded34 and the final 3 measurements from each 
arm were averaged,35 providing one systolic and one diastolic mean value for each arm. 
Ambulatory Blood Pressure Measurement  
Following completion of  sequential and simultaneous resting blood pressure 
measurements,  participants were fitted with an ambulatory blood pressure cuff, first on the right 
arm and then on the left, in order to test for the presence of IADs during activities of daily living 
(Spacelabs 90207 Ambulatory Blood Pressure Monitor, Spacelabs Healthcare, Hertford, UK; 
Appendix D). Due to the exploratory nature of the study, ABPM measurements were only 
collected at times 0, 30 and 60 minutes, as opposed to the typical  24-hour clinical collection 
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period.7 Systolic and diastolic values were averaged to reflect the use of mean 24-hour ABPM as 
the most widely used predictor of cardiovascular risk in clinical practice.30  
Three pairs of right- and left-arm ambulatory measurements were taken in 30-minute 
intervals, yielding 3 systolic and 3 diastolic values in each arm over the course of 1 hour. As with 
sequential, resting measurements, all dual-arm ABPM began in the right arm. After each 
measurement in the right arm, the cuff was transferred to the left arm by the investigator, and left-
arm measurement was initiated by the investigator. After completion of the left-arm 
measurement, the investigator transferred the cuff back to the right arm, and the next right-arm 
measurement began automatically 30 minutes later.7 Throughout the duration of the ABPM 
protocol, participants were allowed to leave the lab and participate in normal daily activities, 
while remaining within the laboratory building. 
At the end of 1 hour, the ambulatory monitor and cuff were removed from the participant, 
and data were uploaded to a computer for analysis. All 3 systolic and diastolic measurements 
were averaged separately for each arm, yielding 1 average systolic and 1 average diastolic 
measurement for each side. 
2.2.5 Statistical Analysis 
First, one-way analyses of variance (ANOVAs) were used to test for differences between 
sequential and simultaneous measurements. Then, to test for differences introduced by monitor 
bias, sequential and simultaneous resting blood pressure values from the first and second testing 
day were pooled and stratified according to arm, and Kolmogorov-Smirnov’s test (due to non-
normality of distribution) determined whether the distributions of resting SBP and DBP differed 
by arm. Also, independent t-tests were used to test for an effect of measurement order (i.e., 
sequential versus simultaneous first) on average directional sIAD and dIAD values, and 
Kolmogorov-Smirnov’s test was again used in cases of non-normally distributed data.  
Directional IADs (i.e., positive or negative, reflecting the side of the arm with the higher 
reading) were determined by subtracting left arm blood pressure values from the corresponding 
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right arm values, and then subsequently converted to absolute IADs (i.e., non-directional, with no 
sign) for analysis of prevalence. Continuous data for all measurements, whether resting or 
ambulatory, systolic or diastolic ,were converted to 4 sets of categorical (i.e., “Yes or “No”) data, 
based on 3 previously used difference thresholds of 10, 15, and 20mmHg,9 and 1 additional 
threshold of 5mmHg (to explore the relationship of age to the development of IADs). Clopper-
Pearson binomial tests of proportions were used to test whether the prevalence of IADs exceeding 
each of these values would differ significantly from zero, as well as to estimate prevalence ranges 
(i.e., 95% confidence intervals) in the general population of young, healthy adults.  
To examine the between-day consistency of IAD magnitude within subjects, two-way 
random intraclass correlation coefficients (ICCs) for directional IADs were used to determine: 1) 
the reliability of all sequential and simultaneous resting IADs between testing days; and 2) the 
reliability of all ambulatory IADs between testing days. Additionally, McNemar’s test of 
binomial distributions was used to test whether there were significant differences between first- 
and second-day prevalence of all IADs. 
As secondary analyses, Pearson’s correlations were used to test for relationships of 
directional IADs with State Anxiety scores (obtained from the STAI-Y; Trait Anxiety scores 
were not included in the analysis) and heart rate. The relationship of directional IADs to body 
mass index (BMI; as calculated from weight and height recorded on the medical questionnaire) 
was also examined in this manner to control for the possibility that obesity might influence IADs. 
As age was not normally distributed, Spearman’s rho was used in place of Pearson’s correlations 
to investigate whether there was a trend in IAD magnitude with increasing age.  
To account for the possibility that Testing Day might affect overall State Anxiety and 
heart rate of the sample, paired t-tests were used to examine differences in first- and second-day 
means, and within-subjects reliability of both State Anxiety and heart rate was examined across 
testing days using two-way random ICCs. Pearson’s correlations also tested for a relationship 
between State Anxiety and heart rate.  
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All data were analyzed using IBM SPSS Statistics 21, and a p value < 0.05 was 
considered statistically significant. Data are presented as mean ± standard deviation (SD), unless 
otherwise specified. 
2.3 RESULTS 
 Mean right- and left-arm blood pressure values from sequential and simultaneous resting, 
and sequential ambulatory measurements for all testing are shown in Table 2. One-way ANOVAs 
revealed no differences between sequential and simultaneous means for right-arm systolic 
measurements, F(71) = 0.017, p = 0.897, right-arm diastolic measurements, F(71) = .016, p = 
0.899, left-arm systolic measurements, F(71) = 0.686, p = 0.410, or left-arm diastolic 
measurements, F(71) = 0.000, p = 0.992. 
Table 2. Average SBP and DBP values from sequential and simultaneous resting and 
sequential ambulatory blood pressure measurements. N=18 
 
 
Sequential Resting 
(mmHg) 
Simultaneous Resting 
(mmHg) 
Ambulatory 
(mmHg) 
 Right Left Right Left Right Left 
Systolic 103+8 103+8 103+9 103+8 127+10 125+9 
Diastolic 58+8 59+8 58+8 59+7 74+8 75+8 
 
2.3.1 Monitor Reliability and Order Effects 
Kolmogorov-Smirnov’s tests revealed no significant difference in the distributions of 
pooled right- and left- arm SBP (right-: 103 + 9, left-: 103 ± 9; p = 0.985) or DBP (right-: 58 + 8, 
left-: 59 + 8; p = 0.071), indicating that right- and left-arm monitors remained unbiased after 
calibration and did not influence the assessment of IADs. With respect to order effects, 
independent t-tests revealed no significant differences (all P > 0.05) between sequential-first (n = 
10) and simultaneous-first (n = 8) groups in sIADs for either sequential measurements (-1 + 
6mmHg vs. 0 + 3mmHg; sequential-first and simultaneous-first, respectively, for Day 1; 1 + 
3mmHg vs. 0 + 5mmHg; sequential-first and simultaneous-first, respectively, for Day 2) or 
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simultaneous measurements (1 + 5mmHg vs. 0 + 3mmHg; sequential-first and simultaneous-first, 
respectively, for Day 1; 0 + 4mmHg vs. 0 + 4mmHg; sequential-first and simultaneous-first, 
respectively, for Day 2). Similarly, an independent t-test found no significant difference between 
groups for simultaneous dIADs on Day 2 (-1 + 3mmHg vs. -2 + 4mmHg, p = 0.742; sequential-
first and simultaneous-first, respectively), and Kolmogorov-Smirnov’s test (due to non-normality 
of distribution) found no significant difference between groups for simultaneous dIADs on Day 1 
(-1 + 3mmHg vs. -2 + 2mmHg, p = 0.560; sequential-first and simultaneous-first, respectively). 
Conversely, the simultaneous-first group had larger sequential dIADs on both Day 1 (0 + 3mmHg 
vs. -3 + 1mmHg, t(12) = -2.601, p = 0.023; sequential-first and simultaneous-first, respectively) 
and Day 2 (0 + 1mmHg vs. -2.5 + 2.2mmHg, Kolmogorov-Smirnov test statistic = 1.845, p = 
0.002; sequential-first and simultaneous-first, respectively). Therefore, measurement order had an 
effect on sequential diastolic measurements alone. 
2.3.2 Prevalence and Reliability of IADs 
Frequencies of absolute IADs for all sequential and simultaneous resting and sequential 
ambulatory measurements, as well as calculated prevalence and Clopper-Pearson estimates of 
prevalence ranges (95% Confidence Intervals [CI]) for both testing days are shown in Table 3. 
Resting, simultaneous dIADs showed a strong, positive correlation between first and 
second testing days (ICC = 0.561, p = 0.006), but no other between-days ICCs for any resting 
IADs, whether systolic or diastolic, were significant (all P > 0.05). Ambulatory sIADs were 
moderately correlated between days (ICC = 0.472, p = 0.021), but ambulatory dIADs were not (p 
= 0.138). All ICCs for between-days comparisons of IADs are shown in Table 4. 
 Prevalence of all resting and ambulatory IADs decreased from the first testing day to the 
second, with the exception of resting, simultaneous sIADs and dIADs >5mmHg but <10mmHg. 
However, McNemar’s test of binomial distributions found that probability distributions from both 
days were equally likely (Table 5), and therefore the decreases in IAD prevalence on the second  
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Table 3. Frequency and prevalence of IADs meeting or exceeding thresholds of 0, 5, 10, 
15 and 20 mmHg for sequential and simultaneous resting sIADs and dIADs and 
sequential ambulatory sIADs and dIADs on Testing Days 1 and 2.  N = 18 
IAD Thresholds by 
Modality 
Day 1 
Frequency 
Day 1 Prevalence 
(%) 
Day 2 
Frequency 
Day 2 Prevalence 
(%) 
Resting IADs  %    [95% CI]  %    [95% CI] 
Sequential sIADs      
               > 0mmHg 18 100  [81.5 – 100] 18 100  [81.5 – 100] 
               > 5mmHg 6 33.3 [13.3 – 59] 5 27.8 [9.7 – 53.5] 
               > 10mmHg 1 5.6   [0.1 - 27.3] 0 0      [0 – 18.5] 
               > 15mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
             > 20mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
Sequential dIADs      
               > 0mmHg 18 100  [81.5 – 100] 18 100  [81.5 – 100] 
               > 5mmHg 2 11.1 [1.4 – 34.7] 0 0      [0 – 18.5] 
               > 10mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
               > 15mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
               > 20mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
Simultaneous sIADs     
               > 0mmHg 18 100  [81.5 – 100] 18 100  [81.5 – 100] 
               > 5mmHg 3 16.7 [3.6 – 41.4] 5 27.8 [9.7 – 53.5] 
               > 10mmHg 2 11.1 [1.4 – 34.7] 0 0      [0 – 18.5] 
               > 15mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
               > 20mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
Simultaneous dIADs     
               > 0mmHg 18 100  [81.5 – 100] 18 100  [81.5 – 100] 
               > 5mmHg 2 11.1 [1.4 – 34.7] 4 22.2 [6.4 – 47.6] 
               > 10mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
               > 15mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
               > 20mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
Ambulatory IADs  %    [95% CI]  %    [95% CI] 
Sequential sIADs      
               > 0mmHg 18 100  [81.5 – 100] 18 100  [81.5 – 100] 
               > 5mmHg 11 61.1 [35.7 – 82.7] 8 44.4 [21.5 – 69.2] 
               > 10mmHg 6 33.3 [13.3 – 59] 1 5.6   [0.1 – 27.3] 
               > 15mmHg 2 11.1 [1.4 – 34.7] 0 0      [0 – 18.5] 
               > 20mmHg 1 5.6   [0.1 – 27.3] 0 0      [0 – 18.5] 
Sequential dIADs      
               > 0mmHg 18 100  [81.5 – 100] 18 100  [81.5 – 100] 
               > 5mmHg 4 22.2 [6.4 – 47.6] 3 16.7 [3.6 – 41.4] 
               > 10mmHg 1 1      [0.1 – 27.3] 0 0      [0 – 18.5] 
               > 15mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
               > 20mmHg 0 0      [0 – 18.5] 0 0      [0 – 18.5] 
N=18; Values are mean + standard deviation; Note: IADs were determined by 
subtracting left arm blood pressure from right arm blood pressure. Values presented are 
absolute (i.e., non-directional, with no sign). 
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Table 4. Two-way random intraclass correlation coefficients (ICCs) between Testing Days 1 
and 2 for sequential and simultaneous sIADs and dIADs and sequential ambulatory sIADs 
and dIADs. N = 18 
 ICC Between Days 1 and 2                                       p 
Resting Sequential sIADs .131 0.297 
Resting Sequential dIADs .327 0.086 
Resting Simultaneous sIADs .148 0.273 
Resting Simultaneous dIADs .561 0.006 
Ambulatory Sequential sIADs .472 0.021 
Ambulatory Sequential dIADs .264 0.138 
 
testing day were not statistically significant. Nevertheless, no single individual had a resting IAD 
exceeding any of the pre-determined thresholds that was consistent across both testing days. 
2.3.3 Effects of State Anxiety, Heart Rate, BMI, and Age 
Means and standard deviations of all variables involved in secondary analysis from both 
testing days are shown in Table 6. Pearson’s correlations between State Anxiety and sequential or 
simultaneous resting IADs were not significant (all P > 0.05). State Anxiety scores from the first 
day were moderately correlated with first-day ambulatory sIADs (r = 0.486, p = 0.041), but no 
other relationships between State Anxiety and ambulatory IADs were found. Heart rate only 
correlated with first-day resting, sequential sIADs (r = -0.538, p =0 .032); BMI was only 
moderately and negatively correlated with second-day resting, simultaneous dIADs (r = -0.481, p 
= 0.043); and age was not significantly correlated with any resting or ambulatory IADs (all P > 
0.05). Furthermore, paired t-tests found no significant difference between mean State Anxiety 
scores from first and second days (p = 0.138), and ICCs demonstrated strong, significant 
relationships of State Anxiety scores within subjects across testing days (ICC = 0.717, p = 0.000). 
ICCs also showed strong within-subjects relationships across testing days for heart rate 
determined during sequential (ICC = 0.855, p = 0.000), simultaneous (ICC = 0.898, p = 0.000), 
and ambulatory (ICC = 0.851, p = 0.000) measurements. Thus, there was strong between-day  
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Table 5. McNemar’s test of binomial distributions for comparison of the likelihood of 
distributions of simultaneous and sequential resting and sequential ambulatory IADs 
meeting or exceeding thresholds of 5, 10, 15, and 20mmHg between Testing Days 1 and 2. 
IAD Thresholds by Measurement Modality Test Statistic Significance (p-value)* 
Resting IADs   
Sequential Systolic    
               > 5mmHg 0.167 0.688 
               > 10mmHg 0.500 0.500 
               > 15mmHg .** .** 
               > 20mmHg .** .** 
Sequential Diastolic    
               > 5mmHg 0.500 0.500 
               > 10mmHg .** .** 
               > 15mmHg .** .** 
               > 20mmHg .** .** 
Simultaneous Systolic    
               > 5mmHg 0.167 0.688 
               > 10mmHg 0.500 0.500 
               > 15mmHg .** .** 
               > 20mmHg .** .** 
Simultaneous Diastolic    
               > 5mmHg 0.000 1.000 
               > 10mmHg .** .** 
               > 15mmHg .** .** 
               > 20mmHg .** .** 
Ambulatory IADs   
Sequential Systolic    
               > 5mmHg 0.444 0.508 
               > 10mmHg 3.200 0.063 
               > 15mmHg 0.500 0.500 
               > 20mmHg 0.000 1.000 
Sequential Diastolic    
               > 5mmHg 0.167 0.688 
               > 10mmHg 0.000 1.000 
               > 15mmHg .** .** 
               > 20mmHg .** .** 
* Exact p-value is displayed because there are fewer than 25 cases. 
 
 
** Test statistic and significance could not be computed because there were 0 cases 
exceeding these thresholds. 
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Table 6. Means and standard deviations of all variables involved in secondary analyses, 
including BMI, state score, heart rate, and sequential and simultaneous resting and 
sequential ambulatory sIADs and dIADs for both Testing Days 1 and 2. 
 Testing Day 1 Testing Day 2 
Variable Mean (+SD) Mean (+SD) 
BMI 25.27+4.52 25.27+4.52 
State Anxiety Score 30+8 29+6 
Heart Rate from resting, sequential measurements (bpm) 63+10 66+10 
Heart Rate from resting, simultaneous measurements (bpm) 63+10 67+9 
Heart Rate from ambulatory measurements (bpm) 64+12 68+11 
Resting, sequential sIADs (mmHg) 1+5 0+4 
Resting, sequential dIADs (mmHg) -2+3 -1+2 
Resting, simultaneous sIADs (mmHg) 0+4 0+4 
Resting, simultaneous dIADs (mmHg) -2+3 -1+2 
Ambulatory, sequential sIADs (mmHg) 3+9 1+6 
Ambulatory, sequential dIADs (mmHg) 0+4 -1+3 
 
reliability of both State Anxiety and heart rate.  Although mean heart rates obtained from 
ambulatory measurements and resting, simultaneous measurements increased by 3bpm, t(15) = -
2.328, p = 0.033, and 4bpm, t(15) = -3.435, p = 0.004, respectively, from first to second testing 
days, and those from resting, sequential measurements also increased non-significantly by 3bpm 
(p = 0.066), only the relationship of heart rate to resting, sequential sIADs changed at the second 
testing day. Finally, no correlations existed between State Anxiety scores and heart rate (all P > 
0.05). Therefore, the IADs described in this study are unrelated to State Anxiety, heart rate, BMI, 
or age. 
2.4 DISCUSSION 
The prevalence and nature (i.e., reliability and clinical relevance) of blood pressure IADs 
in young, healthy adults are not well understood.29 Previous examinations are limited by various 
methodological problems, and to-date no well-controlled, prospective study has investigated the 
prevalence and reliability of IADs in this population. Furthermore, no study has as yet examined 
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the feasibility of dual-arm ABPM for determining IADs in any population. This study therefore 
sought to address some of the concerns with previous literature by selecting a methodology 
better-suited to test for the prevalence and reliability of IADs, by using both sequential and 
simultaneous resting, and sequential ambulatory blood pressure measurements.  
The current protocol improved upon previous methodologies by: limiting recruitment to 
normotensive individuals between the ages of 18 and 40 years, with no known chronic disease, 
acute condition, or over-the-counter or prescription medication that might affect blood pressure; 
repeating measurements on a second day; utilizing both simultaneous and sequential resting 
measurements; assessing multiple IAD thresholds when determining prevalence and reliability; 
and using calibrated, automated measurements, as well as only one investigator, to eliminate 
inter-rater discrepancies and observer bias. 
Three important findings emerged from this study: 1) despite the use of more rigorous 
controls, prevalence of resting IADs determined from a single day of measurements supports 
ranges inferred from previously published work;27, 29 2) IADs are not reliable across testing days; 
and 3) that dual-arm ABPM is feasible, but determining true characteristics of ambulatory IADs 
and the associated clinical implications warrant further investigation. 
2.4.1 IAD Prevalence 
 Prevalence of Resting IADs 
Resting sIADs and dIADs <10mmHg are common in the general population, but are not 
well characterized in young, healthy adults. To address this issue, a smaller threshold IAD of 
5mmHg was examined in the present study. First-day prevalence values of resting sIADs 
>5mmHg were 33.3% for sequential and 16.7% for simultaneous measurements, while dIADs 
>5mmHg were found in 16.7% of participants for both sequential and simultaneous 
measurements. Therefore, in this study of 18 healthy adults (16 men, 2 women) between the ages 
of 18 and 40 years, resting IADs of this magnitude were common. However, the majority of 
participants were in their early-to-mid-20s, and only 2 participants were over 30 years of age. 
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Although results were unchanged when these participants were removed from the analysis (all P 
> 0.05), the prevalence of IADs >5mmHg in this study should still be interpreted cautiously.  
Although previous investigations of resting IADs in young, healthy adults have numerous 
methodological weaknesses, 2 studies have relatively few limitations, allowing for comparison of 
their findings with the prevalence of resting IADs >10mmHg in the present investigation. 
Fotherby and colleagues,27 examining resting IADs in a sample of healthy adults between the 
ages of 18 and 48 years (8 men, 32 women), found simultaneous sIADs >10mmHg in only 1 out 
of 40 participants (~3%; measured 8 times in one visit), and no participant had a dIAD of this 
magnitude. In a much larger sample of 877 young, healthy Israeli Air Force recruits (806 men, 71 
women; mean age 26+10 years), Grossman and colleagues29 documented sequential sIADs and 
dIADs >10mmHg in 111 and 77 participants (~13% and 9%, respectively; measured 2 times in 
one visit).  
The first-day prevalence of sIADs >10mmHg in the present study (5.6% sequential and 
11.1% simultaneous) fall within the range provided by these studies27, 29 and support the validity 
of previous data despite these earlier studies’ use of less stringent controls. Similarly, as in 
Fotherby and colleagues’ study,27 no dIADs >10mmHg appeared. Interestingly, however, 
Grossman and colleagues29 did report a 9% incidence of dIADs >10mmHg. Thus, had the sample 
size in the present study increased, a similar prevalence may have been found. In any case, 
present findings provide supporting evidence for prevalence ranges of 3% to 13% for sIADs and 
0% to 9% for dIADs >10mmHg in the general population of young, healthy adults. 
Finally, as sIADs of 15 to 19mmHg and dIADs of 17 to 20mmHg have previously been 
found in non-CVD individuals,15 this study also sought to determine the prevalence of resting 
sIADs and dIADs exceeding thresholds of 15 and 20mmHg. However, no such IADs were found. 
A recent meta-analysis9 demonstrated that sIADs of 10 to 20mmHg are sufficient for prescription 
of angiographic assessment for the presence of SS, and indicated that the specificities of sIADs 
>15mmHg for PVD and CRVD were very high, meaning that when such differences are found, 
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the presence of these diseases is very likely.9 Therefore, it is unsurprising that no such differences 
were found in a small sample of young, healthy adults. 
Prevalence of Ambulatory IADs 
The feasibility of a dual-arm ABPM protocol for identifying IADs in a young, healthy, 
adult population was also explored in this study. Indeed, sequential ABPM did identify a number 
of IADs, yielding prevalence values of 61.1%, 33.3%, 11.1%, and 5.6% for sIADs >5, 10, 15, and 
20mmHg, respectively, on the first day. Prevalence of first-day dIADs was 22.2% and 5.6% for 
thresholds of 5 and 10mmHg, while no dIADs >15 or 20mmHg were found. 
Only three previous investigations31, 32, 33 have examined IADs in blood pressure using 
ambulatory monitors. One study did not use an ABPM protocol, but compared resting readings 
from two different ambulatory monitors (the Del Mar Avionics Pressurometer IV, Del Mar 
Avionics, Irvine, California, USA, and the Spacelabs 90202, Spacelabs Inc., Redmond, 
Washington, USA) to resting, auscultatory readings.31 Another used two different monitor models 
(the Mobil-O-Graph, I.E.M., Stolberg, Germany, and the Spacelabs 90207, Spacelabs Inc., 
Redmond, Washington, USA) to assess inter-model reliability.32  
The other study33 was the only one to use the same monitor model on both arms (the 
Tycos Quiet-Trak, Tycos-Welch-Allyn, Arden, North Carolina, USA), investigating IADs 
directly, for the purpose of determining which arm should be used in clinical practice for ABPM. 
It found higher values (i.e., 6mmHg SBP and 3mmHg DBP) in the dominant (i.e., right) arm.33 
However, this was a small-scale study using a sample of 10 hypertensive adults (6 men, 4 
women) with a mean age of 45+17 years, and participants were excluded if they did not have a 
resting, sequential sIAD >10mmHg at baseline.33Therefore, the present study is the first to 
directly investigate the existence of ambulatory IADs in a young, healthy adult population, as 
well as the first to investigate their prevalence in any population. 
Interestingly, although identification of IADs using dual-arm ABPM was possible in the 
present study, prevalence values were notably higher on both days than those of the 
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corresponding resting, sequential sIADs and dIADs (see Table 3). Moreover, ABPM identified 
“new” sIADs >5mmHg in 7 participants and >10mmHg in 6 participants who had no resting, 
sequential sIAD of these magnitudes, while finding “new” dIADs of these magnitudes in 3 and 1 
participants, respectively. It also failed to identify sIADs and dIADs >5mmHg in 2 and 3 
participants, respectively. Therefore, dual-arm ABPM appears to have over-estimated the 
prevalence of both sIADs and dIADs when compared to resting prevalence values. This 
discrepancy between resting and ambulatory measurements may be explained by consideration of 
the nature of the dual-arm ABPM protocol employed in the present study. Recent activities, cuff 
transfer and/or participant movement during data acquisition may have alone or collectively 
contributed. 
2.4.2 Reliability of IADs Across Testing Days 
 Reliability of Resting IADs 
 When examining the data of all resting IADs, only those from simultaneous diastolic 
measurements were reliable (see Table 4). It is unclear why no other resting IADs were 
correlated, but the greater similarity across testing days of sequential and simultaneous dIADs 
than sequential and simultaneous sIADs (see Table 4), as well as the greater stability of 
simultaneous measurements than sequential measurements,13 may suggest that simultaneous 
dIADs are the least prone to variation of all resting, dual-arm measurement modalities.  
 As another method of assessing the reliability of resting IADs between days, prevalence 
values of IADs meeting thresholds of 5 and 10mmHg from the second testing day were compared 
with those of the first. The second day of testing demonstrated that simultaneous sIADs and 
dIADs >5 but <10mmHg rose minimally, but the prevalence of all other resting IADs meeting 
threshold values was reduced. Interestingly, resting sequential and simultaneous sIADs 
>10mmHg disappeared altogether (see Table 3). Although the changes in prevalence at the 
second day were not significant (see Table 5), the reduction in IAD prevalence at the second 
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testing day is supported by previous work36, 37 (as discussed below) and may have implications for 
clinical practice if resting IADs are indeed unreliable. 
In a further evaluation of the reliability of IADs, then, individual IADs from the first day 
were compared with corresponding values from the second day, to determine whether prevalence 
values on the second day were made up of individuals who had IADs on the first day. Participants 
had no reliable resting sIADs or dIADs, with the exception of 1 simultaneous dIAD >5mmHg, 
confirming the non-reliability of resting sequential and simultaneous sIADs and sequential dIADs 
across two testing days in this study. The non-reliability of resting IADs therefore calls into 
question both the first-day prevalence and clinical importance of IADs in young, healthy adults. 
Over 80 years ago, Korns and Guinard25 investigated IADs in 1000 young, healthy 
patients aged 16 to 49 years old (731 men, 269 women) using a dual-monitor, simultaneous 
protocol, and reported prevalence values of ~9% for both sIADs and dIADs >10mmHg. The 
investigators then conducted dual-arm resting blood pressure measurements at a later date in 175 
of these participants to determine the reliability of IADs. They reported that IADs disappeared 
over time, or appeared where no IAD difference was previously seen, as was the case in the 
present investigation. Korns and Guinard25 therefore inferred that non-reliable IADs are common 
to all individuals and do not merit concern unless an IAD is shown to be permanent.25 However, 
IADs were determined by simultaneous measurements using separate raters and separate 
sphygmomanometers, and only a single set of measurements at each visit, and therefore 
measurement error may have been responsible for the non-reliability of IADs. Nevertheless, 
Korns and Guinard25 raised an important question that had yet to be addressed in a well-
controlled investigation until the present study, namely, whether resting IADs are reliable in 
young, healthy adults. The answer may have implications for understanding the clinical relevance 
of resting IADs in this population. 
It has been suggested that if IADs are commonly caused by some form of arterial 
obstruction (e.g., PVD or SS),9 then true IADs would demonstrate a degree of permanence over 
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time with respect to magnitude and side of the arm with the higher reading.36, 37 Accordingly, in 
their study of young, healthy Israeli Air Force recruits, Grossman and colleagues29 note that 
atherosclerotic obstruction is an unlikely cause of IADs in young, healthy adults, implying that 
true IADs in this population must have a different etiology.  
Supporting this contention, two prominent investigations in older, hypertensive 
populations have observed reliable IADs in only those individuals with known obstructive arterial 
disease (measured sequentially and simultaneously in a sample of 70 men and 77 women with 
hypertension, mean age 58+48 years),36 or with other co-morbidities such as chronic kidney 
disease, vascular disease, and diabetes (measured sequentially in a sample of 401 men and 20 
women, mean age 63+13 years).37 Furthermore, one study found a decrease in sIAD prevalence 
on the second day,36 and the other observed a 2mmHg decrement in sIAD magnitude over 1 
week.37  
Two important conclusions arose from these studies. First is the suggestion that in the 
absence of arterial obstruction, IADs are impermanent and caused primarily by random variations 
in blood pressure as an intrinsic component of the cardiovascular system.36, 37 Secondly, it was 
suggested that due to decrements in IAD magnitude at a second visit, dual-arm blood pressure 
should be taken on multiple occasions for proper assessment of IADs.37 
The findings of the present study in young, healthy adults support both of these 
suggestions, as resting sIADs and dIADs were not reliable across testing days, and because 
prevalence of nearly all IADs decreased on the second day. They also suggest that if first-day 
prevalence of IADs in this population is primarily reflective of random variation rather than 
pathology, then the prevalence of clinically meaningful IADs is much lower than first-day 
prevalence would indicate. Nevertheless, as this is a small-scale study, further investigation is 
needed to determine the prevalence, reliability, and clinical importance of IADs for young, 
healthy adults. 
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 Reliability of Ambulatory IADs 
ICCs for between-days comparisons of sequential ambulatory IAD magnitudes revealed a 
moderate, significant correlation between first- and second-day sIADs and no relationship 
between first- and second-day dIADs (see Table 4).  
Nevertheless, there was a decrease in prevalence of both sIADs and dIADs meeting all 
pre-determined thresholds, which is consistent with the pattern observed for resting IADs. This 
may indicate that dual-arm ABPM is capable of determining true characteristics of IADs in at 
least one respect (i.e., that prevalence decreases on a second testing day), but further investigation 
is required to determine the most accurate method of assessment. Given the limitations of the 
present protocol, it is therefore suggested that future research should employ a more stringent, 24-
hour, simultaneous ABPM protocol (with two monitors) when examining ambulatory IADs.     
2.4.3 Future Directions and Implications for Clinical Practice 
 The results of this study suggest that there is a need for large-scale investigation into the 
prevalence and reliability of both resting and ambulatory IADs in young, healthy adults. 
Although first-day prevalence values for resting IADs corroborate previous estimates of 3%27 to 
13%29 (sIADs) and 0%27 to 9%29 (dIADs), the non-reliability of these IADs between days calls 
both their true prevalence and clinical relevance into question. 
Similarly, although the results of this study demonstrate the potential of dual-arm ABPM 
to detect IADs and their characteristics, large-scale investigation using a dual-monitor, 
simultaneous protocol is required to determine whether it can provide accurate estimates of IADs 
during activities of daily living, as well as to determine the clinical importance of ambulatory 
IADs. 
In clinical practice, although the results of the present study suggest that prevalence of 
resting IADs is low, and might be even lower when taken on a second day, blood pressure should 
still be taken in both arms when assessing young adults for HT.34 Large-scale investigation is 
required to determine whether reliable IADs exist in this population and whether they indicate 
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pathology, and therefore the precautionary recommendation to assess for HT34 in both arms 
should remain unchanged. Additionally, these measurements should be repeated on a second day 
to ensure that IADs are reliable.36, 37 Further investigation is required before recommendations can 
be made regarding the implementation of dual-arm ABPM in clinical practice. 
2.4.4 Limitations 
There were 4 important limitations to the present study. Firstly, the small sample size (N 
= 18) meant that estimated prevalence ranges were very broad (Table 3), and that every individual 
with an IAD represented an increase of 5.6% prevalence in the sample. It is also possible that 
sample size was a confounding factor in determining the relationships of IADs between days as 
well as with BMI, State Anxiety, heart rate, and age. Nevertheless, prevalence of sIADs 
>10mmHg in the present study (5.6% sequential and 11.1% simultaneous) was within the range 
given by previous investigations (3% to 13%)27, 29 and the non-reproducibility of IADs seems to 
confirm previous suggestions that in the absence of arterial obstruction, IADs are impermanent.36, 
37 However, it is important to note that arm dominance was not taken into consideration in this 
study. Although a review of previous literature10 found that arm dominance was not a factor in 
determining IADs, a basic premise of the present investigation was that much previous research is 
limited by methodological weakness. Therefore, arm dominance may have had some part in the 
assessment of IADs. Furthermore, this study was made up of 16 men and only 2 women, 
preventing analysis of sex differences. Nevertheless, when data from the 2 women were removed, 
results remained unchanged (P > 0.05). 
Finally, as explained above, the single-monitor, sequential ABPM protocol used required 
at least some movement between the measurement of right and left arms, as the cuff was 
transferred from the right arm to the left. Future protocols would benefit from the use of two 
monitors calibrated equally and used in a simultaneous fashion. Better still would be the 
development of a single ambulatory monitor capable of measuring blood pressure in both arms, 
however such a device would require evidence of the usefulness of dual-arm ABPM in prognosis.  
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Taken together, these limitations suggest that the results of this study should be 
interpreted cautiously when applied to the general population of young, healthy adults. 
2.4.5 Conclusions 
The present study supported previous first-day prevalence data for IADs27, 29 despite 
using a more stringent, prospective protocol. Furthermore, it found that IADs were not reliable 
across testing days, and that prevalence of elevated sIADs and dIADs decreased in the whole 
sample at the second testing day, regardless of whether measurements were sequential or 
simultaneous, resting or ambulatory, suggesting that  dual-arm blood pressure should be taken on 
multiple occasions for proper assessment of IADs.37Additionally, in the absence of arterial 
obstruction, IADs appear to be impermanent and may be caused primarily by random variations 
in blood pressure as an intrinsic component of the cardiovascular system.36, 37 Finally, this study 
demonstrated the ability of dual-arm ABPM to identify true characteristics of IADs, while 
highlighting some problems inherent to a sequential ABPM protocol. 
This is the first study to prospectively examine both the prevalence and second-day 
reliability of sIADs and dIADs in young, healthy adults using both sequential and simultaneous 
resting protocols. It is also the first study in any population to examine the feasibility of ABPM 
for assessment of IADs. Future research in this population should therefore: employ similar 
protocols in a larger sample to determine the generalizability of these findings to the population; 
investigate the relationship of non-reliable IADs to adverse cardiovascular outcomes; and 
examine the prevalence, magnitude, and clinical implications of IADs using a dual-monitor, 
simultaneous ABPM protocol. Clinically, the recommendation that physicians take blood 
pressure in both arms at first assessment for HT in young, healthy adults should remain 
unchanged until further data is available.   
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CONSENT TO PARTICIPATE IN RESEARCH 
 
Prevalence of Inter-arm Blood Pressure Differences in Young, Healthy Individuals 
 
You are asked to participate in a research study led by Andrew Friesen, BHK, and Adam 
McMahon, BHK, and overseen by Cheri McGowan, PhD, from the Department of Kinesiology at 
the University of Windsor. Results of this study will contribute to Andrew Friesen`s and Adam 
McMahon`s Masters theses. 
 
If you have any questions or concerns about the research, please feel to contact Andrew Friesen 
via telephone (519-253-3000 ext. 2431) or email (friesena@uwindsor.ca). For questions or 
concerns during non-working hours, please contact Cheri McGowan, PhD via cell phone at 734-
904-8488. 
PURPOSE OF THE STUDY 
 
Differences in blood pressure between arms are sometimes related to the presence of heart- and 
blood vessel-related diseases in older individuals with high blood pressure. For this reason, 
guidelines suggest that doctors should take measures in both arms when assessing a patient’s 
resting blood pressure. Sometimes these measures are taken at the same time (e.g., blood pressure 
is taken in right and left arms at once) or sometimes one right after the other (e.g., blood pressure 
is taken in the right arm, and then when finished, blood pressure is taken in the left arm). 
However, there is not much known about whether this kind of difference exists in younger 
individuals with normal blood pressure who have no obvious health problems. We also do not 
know if differences in blood pressure exist between arms when performing normal daily 
activities. So, the goal of this study is to find out if differences in blood pressure commonly exist 
between arms in young, healthy adults. Specifically, we will find out whether these differences 
can be found at rest and during normal daily activities. 
 
In order to participate in this study, you must meet the following criteria: 
 
1) be aged from 18 to 40 years old; 2) have a resting blood pressure that is within the normal 
range (i.e. below 140/90mmHg; 3) be healthy with no health conditions (short- or long-lasting) 
that might affect blood pressure measurements; and 4) not currently taking prescribed 
medications. 
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In order to participate in this study, you must NOT meet any of the following criteria: 
 
1) be aged below 18 years or above 40 years; 2) have a resting blood pressure higher than 
140/90mmHg; 3) have a short- or long-term health conditions that might affect blood pressure 
measurements; and 4) take prescription medications. 
 
Finally, if you participate in this study, you will be asked to avoid caffeine, alcohol, and vigorous 
exercise for 12 hours, and fast (that is, not eat or drink) for 4 hours prior to arrival in the lab on 
Testing Days 1 and 2. 
 
PROCEDURES 
 
If you volunteer to participate in this study, you will be asked to complete the following: 
 
Eligibility and Familiarization 
 
Visit 1 (Approximately 30 Minutes): 
 
After expressing interest in the study, you will be invited to meet with the study researchers in the 
Physical Activity and Cardiovascular Research lab (Room #240, Human Kinetics Building, 
University of Windsor) to learn about the study in more detail. At this time, all aspects of the 
study will be explained and you will be asked to read a consent form and information sheet 
related to the study. If you are still interested in participating in the study, you will be asked to 
sign both the consent form and letter of information, and will be given the letter of information to 
keep for your personal records.  
 
After completing this process, you will be asked to fill out a brief medical questionnaire so that 
study investigators can determine whether this research is appropriate for you. In addition, you 
will have your resting blood pressure measured to be sure that your blood pressure falls within the 
appropriate range for our study (less than 140/90 mmHg).  A cuff will be placed around your 
upper right arm, and after you sit quietly for 10 minutes, it will inflate briefly and then deflate. 
This will happen automatically 4 times, with 2 minutes between each measurement. The first 
measurement will be discarded, and the remaining 3 values will be averaged.  
 
If you meet all of our criteria, you will be invited back to the lab on a second day for a final test 
of eligibility and a familiarization session. Should you have any questions or concerns regarding 
the study, we will be happy to answer them at any time during your visit. You are free to 
withdraw yourself from the study at any time, with no questions asked. 
 
Visit 2: (Approximately 30 minutes): 
 
After completion of the informed consent and screening process, if you are eligible and still wish 
to participate in this study, you will be invited back to the lab for a final test of eligibility and a 
familiarization session. There are two purposes for the familiarization session. Firstly, you will be 
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reminded of all testing procedures and allowed to practice them in order to ensure your comfort 
with participation. Secondly, practicing the testing procedures helps to minimize any effects of 
nervousness or unfamiliarity on our measures.  
 
Before familiarization, your blood pressure will be measured again, the same way it was on your 
first visit. If the averaged blood pressures from Day 1 and Day 2 are less than 140/90mmHg, you 
will be considered eligible to participate in this study. If you are ineligible, you will receive a 
Kinesiology Research t-shirt as a token of our appreciation for your time and interest in our study. 
 
After final eligibility has been determined and you have undergone familiarization and had all 
questions or concerns addressed, blood pressure measurements between arms will be conducted 
at rest and during normal activities of daily living (ambulatory measurements) on a separate day, 
with repeat testing on a final day. Resting blood pressure measures will be conducted in a quiet, 
temperature-controlled room. Ambulatory measurements are not limited to our lab space, but will 
be taken as you go about your day in the Human Kinetics building. All testing will occur at the 
same time of day, to within 3 hours of your initial testing time. 
 
Testing 
 
Visit 3 - Testing Day 1 (Approximately 3 Hours): 
 
When you arrive in the lab, you will be reminded of the testing procedures and of your ability to 
withdraw from the study at any time. The order of testing (that is, whether measurements happen 
at the same time in both arms first, or whether they happen one arm after the other first) will then 
be determined at random (by chance). You will also be asked to use the bathroom, as a full 
bladder can affect blood pressure. Your agreement with requests to fast (not eat or drink) for 4 
hours and avoid caffeine, alcohol, and vigorous exercise for 12 hours will be recorded. 
 
You will then be seated at a table and fitted with an upper-arm cuff on both right and left arms. 
Following 10 minutes of quiet rest, sequential (one arm, then the other) or same-time (both arms 
together) inflation of the cuffs will begin, depending on the order previously determined. 
Sequential (one arm, then the other) and same-time (both arms together) measurement procedures 
are as follows: 
 
Sequential Resting Blood Pressure Measurement 
 
Inflation of the right upper-arm cuff will begin after you have rested quietly for 10 minutes, and 
blood pressure will be measured. When the right cuff has finished inflating, the second cuff will 
begin to inflate, measuring blood pressure in the left arm. Each cuff will deflate and re-inflate 3 
more times automatically, with 2 minutes of rest between each time. This will give a total of 4 
measurements per arm.  
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Same-Time Resting Blood Pressure Measurement 
 
Inflation of both right and left upper-arm cuffs will begin at the same time after you have rested 
quietly for 10 minutes, and blood pressure will be measured four times, again giving a total of 4 
measurements per arm.  
 
After both of these seated measurements have been taken, both cuffs will be removed, and you 
will be fitted with different blood pressure cuffs on both right and left arms. These new cuffs will 
measure your blood pressure as you go about your day in the Human Kinetics building. Just like 
with the seated measurements, these measurements will be taken in two different ways: sequential 
(one measures after the other) and same-time (both measure at once). Just like the seated 
measurements, the order of these two ways of measuring will be random. 
 
Sequential Ambulatory Blood Pressure Measurement 
 
Blood pressure monitors will be programmed so that measurement in the left arm will happen 1 
minute after measurement in the right arm. Your blood pressure will be measured in this way 
(right arm, then left arm) two more times over the next hour, with 30 minutes between each time. 
During this time, you will be allowed to leave the lab and participate in normal activities, such as 
reading, working, teaching, attending class, or socializing, while remaining within the Human 
Kinetics building. You will be asked not to consume caffeine or exercise during this time, until 
the study is over. 
 
Same-Time Ambulatory Blood Pressure Measurement 
 
Blood pressure monitors will be programmed to take measurements in the left and right arms at 
the same time. Your blood pressure will be measured in this way (both arms at once) two more 
times over the next hour, with 30 minutes between each time. During this time, you will be 
allowed to leave the lab and participate in normal activities, such as reading, working, teaching, 
attending class, or socializing, while remaining within the Human Kinetics building. You will be 
asked not to consume caffeine or exercise during this time, until the study is over. 
 
During transition between sequential and same-time measurements, and at the end of testing, you 
will return to the lab and we will remove the blood pressure monitors from your arms.  
 
Visit 4 - Testing Day 2 (Approximately 3 Hours): 
 
Procedures for Testing Day 2 are the same as for Testing Day 1. 
 
Throughout the study you are encouraged to ask questions or bring up concerns that you have 
regarding your participation. We will also remind you of your ability to withdraw from the study 
at any time, with no questions asked. Your participation or lack of participation in this study will 
have no effect on your ability to participate in future research in our lab. 
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After completion of the study, you will receive a Human Kinetics T-shirt as a token of thanks for 
your participation.  
 
POTENTIAL RISKS AND DISCOMFORTS 
 
Resting and ambulatory blood pressure measurements are non-invasive, and therefore carry very 
little risk of physical harm. However, you may experience numbness and/or tingling in the arm(s) 
being measured during inflation and deflation of the cuff(s).  
 
Please contact study investigators if you feel any negative effects from completing the 
investigation, and/or if you have any questions or concerns. If you experience any negative 
effects during the testing procedure, first line response will be provided. 
 
To the best of our knowledge, there are no significant physical or psychological risks that might 
lead to termination of the study. 
 
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR TO SOCIETY 
 
Although there may be no direct benefit to you as there is no intervention in this study, this 
experiment may help scientists and doctors understand better how often differences in blood 
pressure occur between arms in young, healthy adults. A positive result would give good reason 
for larger studies investigating this relationship. This may contribute to blood pressure 
measurement guidelines in health care settings. Also, larger studies that follow may help us to 
better understand the meaning of between-arm differences for health, and may contribute to 
improved health care practices. 
 
 
COMPENSATION FOR PARTICIPATION 
 
You will receive a Human Kinetics T-shirt for your participation in this study. 
 
CONFIDENTIALITY 
 
Any information that is obtained in connection with this study and that can be identified with you 
will remain confidential and will be revealed only with your permission. 
 
To ensure your confidentiality, following your consent, you will be assigned an identification 
number. Your name will not be mentioned in any publication or presentation, and you will be 
identified only with your identification number on all blood pressure collection tools (electronic 
or otherwise). All paper data  will be stored in the locked laboratory (PACR Lab, Room #240, 
Human Kinetics Building, University of Windsor) and all electronic data will be password 
protected. All paper data will be shredded after 5 years.  
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PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to participate in this study or not. If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind. You may also refuse to answer 
any questions you do not wish to answer and still remain in the study. The investigator(s) may 
withdraw you from this research if circumstances arise.. 
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS 
 
Results of this study will be posted on the University of Windsor’s Research Ethics Board (REB) 
website. 
 
Web address: http://www.uwindsor.ca/reb 
SUBSEQUENT USE OF DATA 
 
These data may be used in subsequent studies, in publications and in presentations.  
 
RIGHTS OF RESEARCH PARTICIPANTS 
 
If you have questions regarding your rights as a research participant, contact:  Research Ethics 
Coordinator, University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext. 
3948; e-mail:  ethics@uwindsor.ca 
SIGNATURE OF RESEARCH PARTICIPANT/LEGAL REPRESENTATIVE 
 
I understand the information provided for the study Prevalence of Inter-arm Blood Pressure 
Differences in Young, Healthy Individuals as described herein.  My questions have been 
answered to my satisfaction, and I agree to participate in this study.  I have been given a copy of 
this form. 
 
______________________________________ 
Name of Participant 
 
______________________________________   ___________________ 
Signature of Participant       Date 
 
SIGNATURE OF INVESTIGATOR 
 
These are the terms under which I will conduct research. 
 
_____________________________________  
 ___________________
_ 
Signature of Investigator      Date 
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LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN RESEARCH 
 
Prevalence of Inter-arm Blood Pressure Differences in Young, Healthy Individuals 
 
You are asked to participate in a research study led by Andrew Friesen, BHK, and Adam 
McMahon, BHK, and overseen by Cheri McGowan, PhD, from the Department of Kinesiology at 
the University of Windsor. Results of this study will contribute to Andrew Friesen`s and Adam 
McMahon`s Masters theses. 
 
If you have any questions or concerns about the research, please feel to contact Andrew Friesen 
via telephone (519-253-3000 ext. 2431) or email (friesena@uwindsor.ca). For questions or 
concerns during non-working hours, please contact Cheri McGowan, PhD via cell phone at 734-
904-8488. 
PURPOSE OF THE STUDY 
 
Differences in blood pressure between arms are sometimes related to the presence of heart- and 
blood vessel-related diseases in older individuals with high blood pressure. For this reason, 
guidelines suggest that doctors should take measures in both arms when assessing a patient’s 
resting blood pressure. Sometimes these measures are taken at the same time (e.g., blood pressure 
is taken in right and left arms at once) or sometimes one right after the other (e.g., blood pressure 
is taken in the right arm, and then when finished, blood pressure is taken in the left arm). 
However, there is not much known about whether this kind of difference exists in younger 
individuals with normal blood pressure who have no obvious health problems. We also do not 
know if differences in blood pressure exist between arms when performing normal daily 
activities. So, the goal of this study is to find out if differences in blood pressure commonly exist 
between arms in young, healthy adults. Specifically, we will find out whether these differences 
can be found at rest and during normal daily activities. 
 
In order to participate in this study, you must meet the following criteria: 
 
1) be aged from 18 to 40 years old; 2) have a resting blood pressure that is within the normal 
range (i.e. below 140/90mmHg; 3) be healthy with no health conditions (short- or long-lasting) 
that might affect blood pressure measurements; and 4) not currently taking prescribed 
medications. 
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In order to participate in this study, you must NOT meet any of the following criteria: 
 
1) be aged below 18 years or above 40 years; 2) have a resting blood pressure higher than 
140/90mmHg; 3) have a short- or long-term health conditions that might affect blood pressure 
measurements; and 4) take prescription medications. 
 
Finally, if you participate in this study, you will be asked to avoid caffeine, alcohol, and vigorous 
exercise for 12 hours, and fast (that is, not eat or drink) for 4 hours prior to arrival in the lab on 
Testing Days 1 and 2. 
 
PROCEDURES 
 
If you volunteer to participate in this study, you will be asked to complete the following: 
 
Eligibility and Familiarization 
 
Visit 1 (Approximately 30 Minutes): 
 
After expressing interest in the study, you will be invited to meet with the study researchers in the 
Physical Activity and Cardiovascular Research lab (Room #240, Human Kinetics Building, 
University of Windsor) to learn about the study in more detail. At this time, all aspects of the 
study will be explained and you will be asked to read a consent form and information sheet 
related to the study. If you are still interested in participating in the study, you will be asked to 
sign both the consent form and letter of information, and will be given the letter of information to 
keep for your personal records.  
 
After completing this process, you will be asked to fill out a brief medical questionnaire so that 
study investigators can determine whether this research is appropriate for you. In addition, you 
will have your resting blood pressure measured to be sure that your blood pressure falls within the 
appropriate range for our study (less than 140/90 mmHg).  A cuff will be placed around your 
upper right arm, and after you sit quietly for 10 minutes, it will inflate briefly and then deflate. 
This will happen automatically 4 times, with 2 minutes between each measurement. The first 
measurement will be discarded, and the remaining 3 values will be averaged.  
 
If you meet all of our criteria, you will be invited back to the lab on a second day for a final test 
of eligibility and a familiarization session. Should you have any questions or concerns regarding 
the study, we will be happy to answer them at any time during your visit. You are free to 
withdraw yourself from the study at any time, with no questions asked. 
 
Visit 2: (Approximately 30 minutes): 
 
After completion of the informed consent and screening process, if you are eligible and still wish 
to participate in this study, you will be invited back to the lab for a final test of eligibility and a 
familiarization session. There are two purposes for the familiarization session. Firstly, you will be 
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reminded of all testing procedures and allowed to practice them in order to ensure your comfort 
with participation. Secondly, practicing the testing procedures helps to minimize any effects of 
nervousness or unfamiliarity on our measures.  
 
Before familiarization, your blood pressure will be measured again, the same way it was on your 
first visit. If the averaged blood pressures from Day 1 and Day 2 are less than 140/90mmHg, you 
will be considered eligible to participate in this study. If you are ineligible, you will receive a 
Kinesiology Research t-shirt as a token of our appreciation for your time and interest in our study. 
 
After final eligibility has been determined and you have undergone familiarization and had all 
questions or concerns addressed, blood pressure measurements between arms will be conducted 
at rest and during normal activities of daily living (ambulatory measurements) on a separate day, 
with repeat testing on a final day. Resting blood pressure measures will be conducted in a quiet, 
temperature-controlled room. Ambulatory measurements are not limited to our lab space, but will 
be taken as you go about your day in the Human Kinetics building. All testing will occur at the 
same time of day, to within 3 hours of your initial testing time. 
 
Testing 
 
Visit 3 - Testing Day 1 (Approximately 3 Hours): 
 
When you arrive in the lab, you will be reminded of the testing procedures and of your ability to 
withdraw from the study at any time. The order of testing (that is, whether measurements happen 
at the same time in both arms first, or whether they happen one arm after the other first) will then 
be determined at random (by chance). You will also be asked to use the bathroom, as a full 
bladder can affect blood pressure. Your agreement with requests to fast (not eat or drink) for 4 
hours and avoid caffeine, alcohol, and vigorous exercise for 12 hours will be recorded. 
 
You will then be seated at a table and fitted with an upper-arm cuff on both right and left arms. 
Following 10 minutes of quiet rest, sequential (one arm, then the other) or same-time (both arms 
together) inflation of the cuffs will begin, depending on the order previously determined. 
Sequential (one arm, then the other) and same-time (both arms together) measurement procedures 
are as follows: 
 
Sequential Resting Blood Pressure Measurement 
 
Inflation of the right upper-arm cuff will begin after you have rested quietly for 10 minutes, and 
blood pressure will be measured. When the right cuff has finished inflating, the second cuff will 
begin to inflate, measuring blood pressure in the left arm. Each cuff will deflate and re-inflate 3 
more times automatically, with 2 minutes of rest between each time. This will give a total of 4 
measurements per arm.  
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Same-Time Resting Blood Pressure Measurement 
 
Inflation of both right and left upper-arm cuffs will begin at the same time after you have rested 
quietly for 10 minutes, and blood pressure will be measured four times, again giving a total of 4 
measurements per arm.  
 
After both of these seated measurements have been taken, both cuffs will be removed, and you 
will be fitted with different blood pressure cuffs on both right and left arms. These new cuffs will 
measure your blood pressure as you go about your day in the Human Kinetics building. Just like 
with the seated measurements, these measurements will be taken in two different ways: sequential 
(one measures after the other) and same-time (both measure at once). Just like the seated 
measurements, the order of these two ways of measuring will be random. 
 
Sequential Ambulatory Blood Pressure Measurement 
 
Blood pressure monitors will be programmed so that measurement in the left arm will happen 1 
minute after measurement in the right arm. Your blood pressure will be measured in this way 
(right arm, then left arm) two more times over the next hour, with 30 minutes between each time. 
During this time, you will be allowed to leave the lab and participate in normal activities, such as 
reading, working, teaching, attending class, or socializing, while remaining within the Human 
Kinetics building. You will be asked not to consume caffeine or exercise during this time, until 
the study is over. 
 
Same-Time Ambulatory Blood Pressure Measurement 
 
Blood pressure monitors will be programmed to take measurements in the left and right arms at 
the same time. Your blood pressure will be measured in this way (both arms at once) two more 
times over the next hour, with 30 minutes between each time. During this time, you will be 
allowed to leave the lab and participate in normal activities, such as reading, working, teaching, 
attending class, or socializing, while remaining within the Human Kinetics building. You will be 
asked not to consume caffeine or exercise during this time, until the study is over. 
 
During transition between sequential and same-time measurements, and at the end of testing, you 
will return to the lab and we will remove the blood pressure monitors from your arms.  
 
Visit 4 - Testing Day 2 (Approximately 3 Hours): 
 
Procedures for Testing Day 2 are the same as for Testing Day 1. 
 
Throughout the study you are encouraged to ask questions or bring up concerns that you have 
regarding your participation. We will also remind you of your ability to withdraw from the study 
at any time, with no questions asked. Your participation or lack of participation in this study will 
have no effect on your ability to participate in future research in our lab. 
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After completion of the study, you will receive a Human Kinetics T-shirt as a token of thanks for 
your participation.  
 
POTENTIAL RISKS AND DISCOMFORTS 
 
Resting and ambulatory blood pressure measurements are non-invasive, and therefore carry very 
little risk of physical harm. However, you may experience numbness and/or tingling in the arm(s) 
being measured during inflation and deflation of the cuff(s).  
 
Please contact study investigators if you feel any negative effects from completing the 
investigation, and/or if you have any questions or concerns. If you experience any negative 
effects during the testing procedure, first line response will be provided. 
 
To the best of our knowledge, there are no significant physical or psychological risks that might 
lead to termination of the study. 
 
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR TO SOCIETY 
 
Although there may be no direct benefit to you as there is no intervention in this study, this 
experiment may help scientists and doctors understand better how often differences in blood 
pressure occur between arms in young, healthy adults. A positive result would give good reason 
for larger studies investigating this relationship. This may contribute to blood pressure 
measurement guidelines in health care settings. Also, larger studies that follow may help us to 
better understand the meaning of between-arm differences for health, and may contribute to 
improved health care practices. 
  
 
COMPENSATION FOR PARTICIPATION 
 
You will receive a Human Kinetics T-shirt for your participation in this study. 
 
CONFIDENTIALITY 
 
Any information that is obtained in connection with this study and that can be identified with you 
will remain confidential and will be revealed only with your permission. 
 
To ensure your confidentiality, following your consent, you will be assigned an identification 
number. Your name will not be mentioned in any publication or presentation, and you will be 
identified only with your identification number on all blood pressure collection tools (electronic 
or otherwise). All paper data will be stored in the locked laboratory (PACR Lab, Room #240, 
Human Kinetics Building, University of Windsor) and all electronic data will be password 
protected. All paper data will be shredded after 5 years.  
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PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to participate in this study or not. If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind. You may also refuse to answer 
any questions you do not wish to answer and still remain in the study. The investigator(s) may 
withdraw you from this research if circumstances arise.. 
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS 
 
Results of this study will be posted on the University of Windsor’s Research Ethics Board (REB) 
website. 
 
Web address: http://www.uwindsor.ca/reb 
SUBSEQUENT USE OF DATA 
 
These data may be used in subsequent studies, in publications and in presentations.  
 
RIGHTS OF RESEARCH PARTICIPANTS 
 
If you have questions regarding your rights as a research participant, contact:  Research Ethics 
Coordinator, University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext. 
3948; e-mail:  ethics@uwindsor.ca 
SIGNATURE OF RESEARCH PARTICIPANT/LEGAL REPRESENTATIVE 
 
I understand the information provided for the study Prevalence of Inter-arm Blood Pressure 
Differences in Young, Healthy Individuals as described herein.  My questions have been 
answered to my satisfaction, and I agree to participate in this study.  I have been given a copy of 
this form. 
 
______________________________________ 
Name of Participant 
 
______________________________________   ___________________ 
Signature of Participant       Date 
 
SIGNATURE OF INVESTIGATOR 
 
These are the terms under which I will conduct research. 
 
_____________________________________  
 ___________________
_ 
Signature of Investigator      Date 
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Appendix B – Ethics Clearance 
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Today's Date: June 05, 2013 
Principal Investigator: Mr. A Friesen 
REB Number: 30796 
Research Project Title: REB# 13-063 "Prevalence of Inter-arm Blood Pressure Differences in Young, Healthy 
Individuals"  
Clearance Date: June 5, 2013 
Project End Date: August 30, 2013  
Milestones: 
Renewal Due-2013/08/30(Pending) 
______________________________________________________________________________ 
This is to inform you that the University of Windsor Research Ethics Board (REB), which is organized and operated 
according to the Tri-Council Policy Statement and the University of Windsor Guidelines for Research Involving Human 
Subjects, has granted approval to your research project on the date noted above. This approval is valid only until the 
Project End Date. 
A Progress Report or Final Report is due by the date noted above. The REB may ask for monitoring information at 
some time during the project’s approval period. 
During the course of the research, no deviations from, or changes to, the protocol or consent form may be initiated 
without prior written approval from the REB. Minor change(s) in ongoing studies will be considered when submitted 
on the Request to Revise form. 
Investigators must also report promptly to the REB: 
a) changes increasing the risk to the participant(s) and/or affecting significantly the conduct of the study; 
b) all adverse and unexpected experiences or events that are both serious and unexpected; 
c) new information that may adversely affect the safety of the subjects or the conduct of the study. 
Forms for submissions, notifications, or changes are available on the REB website: www.uwindsor.ca/reb. If your data 
is going to be used for another project, it is necessary to submit another application to the REB. 
We wish you every success in your research.  
 
Pierre Boulos, Ph.D.  
Chair, Research Ethics Board 
Essex Hall, Room #116 
University of Windsor 
519-253-3000 ext. 3948 
Email: ethics@uwindsor.ca 
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Appendix C – Medical Questionnaire 
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Medical Questionnaire 
 
Last Name: _______________________________  First Name: 
__________________________________ 
Address: ________________________________ City ______________________ Province 
___________ 
Height ________ Weight ________ 
Date of Birth _________________ Home Phone # ________________________ 
FOR EMERGENCY NOTIFY:  Name __________________________ Relationship _____________ 
Address __________________________________________ ____ Phone __________________ 
Family Doctor’s Name ____________________________ Date of Last Physical ______________ 
Please Check Yes or NO:       YES       NO 
1. Have you ever been hospitalized?  
  
If yes, please specify:________________________________ 
 Have you ever had surgery? ……………………………………………………………... 
  If yes, please specify: ________________________________ 
 Have you ever had a coronary angioplasty?........................................... 
  If yes, when? _______________________________________ 
 Have you ever had a coronary bypass surgery? ………………………………….. 
  If yes, when? _______________________________________ 
 Are you scheduled to have an angioplasty or bypass surgery? …………... 
  If yes, when? _______________________________________ 
2. Are you presently taking any medications or pills (including aspirin        
     and other over-the-counter medication…………………………………… 
If yes, please specify: _________________________________ 
 Are you presently taking any vitamins, supplements and/or herbal  
 supplements?.......................................................................................... 
  If yes, please specify: _________________________________ 
3. Do you have any allergies (medicine, food, bees or other stinging  
insects)? …………………………………………………………………………………………….... 
If yes, please specify: _________________________________ 
4. Do you have any type of cardiovascular disease? ………………………… 
If yes, please specify: _________________________________ 
 Do you have high blood pressure (hypertension) or low blood pressure 
(hypotension)? …………………………………………………………………………………….. 
Have you ever been told you have a kidney problem? ………………………… 
Have you ever been told that you have a stomach problem? ……………… 
Have you ever been told you have hypercholesterolemia (ie. high levels 
of cholesterol)?........................................................................................ 
  
Please Check Yes or NO:       YES       NO 
Have you ever been told that you have a heart problem? …………………… 
 If yes, please specify: _________________________________ 
Have you ever been told that you have a heart murmur? ……………………. 
Do you have a machine that regulates your heart beat? ……………………… 
Have you ever had racing of your heart or skipped heartbeats? …………. 
Has anyone in your family died of heart problems or sudden death 
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before the age of 50 years? ………………………………………………………………….. 
5. Do you have diabetes?...................................................................... 
6. Do you have asthma or any other breathing problems? ……………….. 
7. Do you have any psychological history (ie. psychosis, eating disorders,  
maniac or bipolar disorder)? ………………………………………………………………… 
8. Have you had any other medical problems  
(infectious mononucleosis, etc.)? ………………………………………………………... 
9. Have you had any medical problems since your last physical? ……… 
10. Do you smoke? ……………………………………………………………………………… 
 
Please explain any physical limitations that may prevent you from completing this study: 
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Appendix D – Blood Pressure Monitors and Digital Manometer 
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Dinamap Carescape v100, Critikon, Tampa, Florida, USA 
 
 
Spacelabs 90207 Ambulatory Blood Pressure Monitor, SpaceLabs Inc., Redmond, Washington, 
USA 
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Digital Manometer 840081, Sper Scientific, Scottsdale, Arizona 
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Appendix E - Raw Data for Chapter 2 
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1. Baseline characteristics of all participants. 
Participant Age (Years) Sex 
Body Mass 
Index 
Resting SBP 
(mmHg) 
Resting 
DBP 
(mmHg) 
Resting 
Heart Rate* 
(bpm) 
1 26 M 22.14 101 55 - 
2 28 M 22.80 103 61 - 
3 23 M 22.37 98 53 58 
4 22 M 26.87 102 54 49 
5 23 M 21.58 97 52 61 
6 22 M 23.24 99 51 62 
7 21 M 29.28 119 69 72 
8 23 F 21.45 93 61 83 
9 38 F 18.70 97 53 71 
10 25 M 29.26 110 62 67 
11 25 M 34.16 115 72 69 
12 21 M 21.14 101 65 62 
13 32 M 26.62 107 69 56 
14 23 M 23.49 94 55 56 
15 20 M 26.60 102 44 54 
16 23 M 23.67 117 69 63 
17 26 M 25.84 98 55 74 
18 24 M 35.61 109 57 76 
Mean(SD) 24.72(4.36) 16M, 2F 25.27(4.51) 103(9) 59(8) 65(9) 
* Resting Heart Rate data represent averages from sequential and simultaneous resting measurements from Testing 
Days 1 and 2, as Heart Rate data were not collected at baseline. 
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2a. Systolic and diastolic blood pressure (SBP and DBP, respectively) of all participants from 
sequential resting measurements on Testing Days 1 and 2. 
 Testing Day 1 Testing Day 2 
Right Arm Left Arm Right Arm Left Arm 
 SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
1 99.7 1.4 50.7 0.5 102.3 0.7 55.3 0.7 104.0 0.9 53.7 0.9 97.3 1.3 56.3 1.0 
2 102.7 0.9 61.0 0.3 100.0 0.9 64.3 0.2 101.7 0.7 62.3 1.1 107.0 0.9 67.0 0.3 
3 95.3 0.2 51.3 0.2 95.3 0.4 54.0 0.3 98.0 0.6 53.3 0.5 98.3 0.9 51.0 0.6 
4 109.0 1.4 56.0 0.3 102.0 0.7 52.7 0.7 101.3 1.2 52.7 0.9 99.7 1.7 54.0 0.6 
5 98.0 1.2 53.0 0.0 98.3 0.9 53.7 1.1 94.7 0.2 47.3 0.2 91.3 2.3 48.0 0.3 
6 102.7 0.9 48.0 1.0 93.7 1.0 47.3 1.0 101.7 0.8 52.3 0.4 100.7 0.2 51.7 0.2 
7 115.7 1.0 69.7 0.7 127.0 1.2 70.0 0.9 109.3 1.4 66.0 0.7 113.0 2.1 67.0 1.0 
8 90.3 1.3 60.0 1.0 97.3 0.7 58.7 1.3 94.0 2.1 64.3 0.7 95.3 1.3 62.0 1.0 
9 94.7 0.9 52.3 0.5 97.7 1.3 56.7 0.5 93.3 2.6 53.7 0.7 99.3 0.9 53.3 0.2 
10 99.3 0.5 57.7 1.0 102.7 2.3 60.7 0.2 117.7 2.3 62.3 0.9 112.3 1.8 62.7 0.8 
11 114.0 1.2 68.0 0.3 110.3 0.7 72.3 1.6 116.0 2.1 73.3 0.5 117.3 2.4 75.7 0.7 
12 93.7 2.0 59.0 0.9 100.3 1.0 63.0 0.7 101.3 0.9 66.7 0.5 102.0 0.3 68.0 0.3 
13 108.0 0.3 71.0 1.0 108.3 1.3 72.7 1.5 106.7 1.0 70.7 0.4 109.0 1.0 72.7 0.9 
14 96.7 0.9 56.7 0.9 96.3 0.5 51.7 0.2 91.3 2.1 54.7 0.2 92.3 0.5 54.7 0.2 
15 94.7 0.5 42.0 0.7 91.7 0.8 45.0 0.9 109.7 0.5 43.3 1.0 106.0 0.0 46.0 1.9 
16 114.0 0.3 71.7 1.9 116.7 0.8 73.7 1.0 121.0 0.9 68.7 1.7 115.7 0.9 66.3 1.7 
17 98.0 2.1 56.0 0.9 99.3 0.5 57.3 0.4 91.0 1.2 51.3 0.2 95.3 1.2 55.7 0.4 
18 108.7 1.3 53.3 0.4 113.7 0.5 58.3 1.1 105.0 0.6 56.0 1.2 105.3 0.4 59.3 0.2 
Mean 102.0 1.0 57.6 0.7 102.9 0.9 59.3 0.8 103.2 1.2 58.5 0.7 103.2 1.1 59.5 0.7 
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2b. Systolic and diastolic blood pressure (SBP and DBP, respectively) of all participants from 
simultaneous resting measurements on Testing Days 1 and 2. 
 Testing Day 1 Testing Day 2 
Right Arm Left Arm Right Arm Left Arm 
 SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
1 99.3 1.3 52.7 0.2 103.7 0.7 57.0 0.0 101.3 1.0 57.7 0.5 99.7 0.8 58.3 0.5 
2 100.0 0.9 58.0 1.2 99.7 2.4 59.3 0.7 101.3 0.2 58.3 0.2 106.3 1.1 60.3 0.4 
3 99.7 1.9 54.3 0.4 99.0 1.7 55.0 0.3 94.3 0.9 51.3 0.2 95.3 0.7 52.3 0.5 
4 106.3 1.1 52.7 0.2 95.7 0.5 54.3 0.5 100.3 3.1 51.0 0.9 97.0 0.9 58.0 0.3 
5 100.3 0.7 53.3 0.9 101.3 0.7 56.7 0.4 97.0 1.0 52.3 0.8 95.3 0.4 54.3 0.5 
6 101.3 1.4 52.0 0.7 97.3 0.5 48.3 1.0 97.0 0.9 51.7 0.5 93.0 0.0 48.3 1.1 
7 129.3 30.6 68.0 16.6 118.0 29.5 70.0 17.0 113.3 0.9 72.0 0.6 122.0 1.0 70.3 0.5 
8 93.0 1.2 59.7 0.4 93.7 0.9 60.0 1.2 92.0 3.3 61.0 0.9 92.0 1.2 59.7 0.9 
9 97.3 1.0 53.7 0.7 98.7 0.7 56.7 0.7 100.3 1.1 49.7 0.5 94.7 1.1 52.3 0.4 
10 100.0 1.2 58.0 1.8 104.3 2.2 61.0 1.6 113.7 1.3 62.0 0.9 111.0 3.1 64.7 0.2 
11 115.0 1.9 65.3 1.0 111.0 0.7 71.7 1.0 116.3 1.3 70.3 0.4 115.7 0.4 75.0 0.3 
12 97.0 0.7 64.3 1.0 99.0 0.6 64.7 0.2 103.7 1.0 67.0 0.9 109.0 0.3 66.3 0.5 
13 104.3 0.5 64.3 0.2 101.0 0.6 66.7 0.7 108.0 0.9 69.7 0.5 107.0 0.3 70.7 0.7 
14 92.7 0.9 58.7 0.5 96.3 0.5 56.0 0.7 87.3 2.2 56.0 0.3 90.7 1.8 54.3 0.5 
15 96.7 0.5 43.3 0.9 95.7 0.2 47.0 0.6 110.0 0.6 40.0 0.3 107.3 0.2 45.0 0.3 
16 113.3 1.4 72.0 1.7 112.7 1.4 69.0 1.6 121.7 0.8 66.3 0.7 114.3 0.5 64.7 1.0 
17 101.7 1.2 51.0 0.7 103.3 1.1 58.3 2.9 93.0 1.0 53.7 0.4 92.0 1.0 54.0 0.3 
18 106.0 1.0 55.0 0.6 112.0 0.9 57.3 0.5 105.0 1.0 55.0 0.6 109.3 0.5 60.3 1.1 
Mean 103.0 2.7 57.6 1.7 102.4 2.5 59.4 1.8 103.1 1.3 58.1 0.6 102.9 0.9 59.4 0.6 
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2c. Systolic and diastolic blood pressure (SBP and DBP, respectively) of all participants from 
sequential ambulatory measurements on Testing Days 1 and 2. 
 Testing Day 1 Testing Day 2 
Right Arm Left Arm Right Arm Left Arm 
 SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
SBP+SD 
(mmHg) 
DBP+SD 
(mmHg) 
1 125.7 0.9 75.3 1.2 121.3 3.3 77.7 3.4 132.3 1.6 75.0 0.9 131.7 2.0 82.7 2.5 
2 134.0 2.4 83.3 1.2 129.3 3.2 83.7 0.9 129.7 4.1 81.0 2.1 132.7 0.4 81.3 1.4 
3 129.7 0.9 77.7 1.9 128.3 2.6 78.7 1.6 129.7 3.3 77.7 1.4 123.7 3.0 76.7 1.6 
4 138.5 33.7 73.5 17.8 115.5 28.0 66.5 16.2 123.7 0.7 65.0 1.4 117.0 2.6 65.7 0.5 
5 118.3 3.3 69.3 1.9 121.3 1.6 74.3 2.0 121.7 4.1 61.7 3.9 114.3 0.2 66.3 0.2 
6 126.7 0.5 71.7 1.8 124.7 0.7 71.7 4.7 120.3 2.0 64.7 1.7 121.3 0.5 69.0 2.1 
7 127.5 31.5 78.5 19.2 124.5 30.3 78.5 19.1 141.0 2.4 86.7 2.3 140.7 2.6 87.7 1.7 
8 111.3 1.4 71.3 0.8 105.3 2.5 72.3 2.9 114.7 0.7 74.3 1.4 108.3 0.4 73.0 0.9 
9 128.3 3.8 76.7 2.2 125.7 1.8 78.0 0.3 123.0 2.9 76.3 1.6 123.0 1.2 77.0 1.8 
10 127.7 1.0 78.0 1.2 121.3 3.5 76.7 1.6 140.3 3.7 78.7 4.0 139.3 1.2 77.0 3.7 
11 140.0 1.4 80.3 2.9 127.0 3.3 79.3 1.1 127.0 3.6 76.3 0.7 129.0 0.0 82.7 2.1 
12 120.0 2.8 71.0 1.7 109.7 1.2 67.7 1.4 121.7 2.6 77.3 4.1 125.3 3.4 80.3 2.5 
13 84.3 30.7 54.0 19.8 85.3 31.2 55.3 20.5 136.0 0.9 90.3 1.1 130.7 1.2 89.3 1.1 
14 103.3 3.1 64.7 3.2 120.3 4.3 67.7 1.5 103.7 2.9 62.3 0.5 111.7 0.9 61.3 0.7 
15 118.7 1.0 56.3 2.3 130.3 1.9 64.0 0.9 121.3 1.2 66.7 4.7 130.7 2.6 67.0 5.6 
16 139.0 1.2 87.7 1.6 125.0 2.5 75.7 0.5 138.7 1.1 83.7 4.7 125.3 3.4 79.7 2.6 
17 138.7 2.6 80.0 0.6 130.7 1.6 84.0 2.4 130.0 4.3 74.7 4.4 134.3 2.9 75.3 2.3 
18 130.7 2.3 80.7 1.0 138.0 1.5 80.3 1.3 132.0 3.9 75.0 1.7 136.3 1.7 79.0 2.1 
Mean 124.6 6.9 73.9 4.6 121.3 6.9 74.0 4.6 127.0 2.6 74.9 2.4 126.4 1.7 76.2 2.0 
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3a. Resting IADs of all participants 
Participant Modality Systolic IADs (mmHg) Diastolic IADs (mmHg) 
Day 1 Day 2 Day 1 Day 2 
1 
 
Simultaneous -4 2 -4 -1 
Sequential -3 7 -5 -3 
2 Simultaneous 0 -5 -1 -2 
Sequential 3 -5 -3 -5 
3 Simultaneous 1 -1 -1 -1 
Sequential 0 0 -3 2 
4 Simultaneous 11 3 -2 -7 
Sequential 7 2 3 -1 
5 Simultaneous -1 2 -3 -2 
Sequential 0 3 -1 -1 
6 Simultaneous 4 4 4 3 
Sequential 9 1 1 1 
7 Simultaneous 11 -9 -5 2 
Sequential -11 -4 0 -1 
8 Simultaneous -1 0 0 1 
Sequential -7 -1 1 2 
9 Simultaneous -1 6 -3 -3 
Sequential -3 -6 -4 0 
10 Simultaneous -4 3 -3 -3 
Sequential -3 5 -3 0 
11 Simultaneous 4 1 -6 -5 
Sequential 4 -1 -4 -2 
12 Simultaneous -2 -5 0 1 
Sequential -7 -1 -4 -1 
13 Simultaneous 3 1 -2 -1 
Sequential 0 -2 -2 -2 
14 Simultaneous -4 -3 3 2 
Sequential 0 -1 5 0 
15 Simultaneous 1 3 -4 -5 
Sequential 3 4 -3 -3 
16 Simultaneous 1 7 3 2 
Sequential -3 5 -2 2 
17 Simultaneous -2 1 -7 0 
Sequential -1 -4 -1 -4 
18 Simultaneous -6 -4 -2 -5 
Sequential -5 0 -5 -3 
Values represent directional IADs. Negative values indicate that blood pressure was higher in the left arm.  
 
 
 
 
90 
 
3b. Ambulatory IADs of all participants 
Participant Modality Systolic IADs (mmHg) Diastolic IADs (mmHg) 
Day 1 Day 2 Day 1 Day 2 
1 
 
Sequential 4 1 -2 -8 
 
2 Sequential 5 -3 0 0 
3 Sequential 1 6 -1 1 
4 Sequential 23 7 7 -1 
5 Sequential -3 7 -5 -5 
6 Sequential 2 -1 0 -4 
7 Sequential 1 0 -3 -1 
8 Sequential 6 6 -1 1 
9 Sequential 3 0 -1 -1 
10 Sequential 6 1 1 2 
11 Sequential 13 -2 1 -6 
12 Sequential 10 -4 3 -3 
13 Sequential -1 5 -1 1 
14 Sequential -17 -8 -3 1 
15 Sequential -12 -9 -8 0 
16 Sequential 14 13 12 4 
17 Sequential 8 -4 -4 -1 
18 Sequential -7 -4 0 -4 
Values represent directional IADs. Negative values indicate that blood pressure was higher in the left arm.  
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4. State Anxiety and heart rate Testing Days 1 and 2 
 Testing Day 1 Testing Day 2 
Participant 
State 
Anxiety 
Score 
Resting 
Seq. 
Heart 
Rate 
(bpm) 
Resting 
Sim. 
Heart 
Rate 
(bpm) 
ABPM 
Heart 
Rate 
(bpm) 
State 
Anxiety 
Score 
Resting 
Seq. 
Heart 
Rate 
(bpm) 
Resting 
Sim. Heart 
Rate 
(bpm) 
ABPM 
Heart 
Rate 
(bpm) 
1 32 N/A N/A 59 30 N/A N/A 62 
2 41 N/A N/A 50 30 N/A N/A 50 
3 20 60 58 56 21 56 59 56 
4 30 47 46 48 30 52 53 47 
5 25 60 59 60 34 62 63 62 
6 24 62 64 62 20 60 63. 64 
7 28 70 71 75 33 73 73 76 
8 35 84 80 86 36 85 84 81 
9 36 62 66 64 34 78 79 77 
10 48 70 69 71 33 65 66 71 
11 24 70 69 68 23 67 70 66 
12 41 60 60 60 40 65 63 77 
13 25 51 58 62 21 52 62 71 
14 20 51 50 52 23 61 61 61 
15 21 51 53 58 20 56 55 57 
16 33 63 59 59 36 66 65 71 
17 32 72 72 85 29 77 76 80 
18 25 76 75 83 25 75 76 87 
Mean(SD) 30(8) 63.0(10)† 63.0(9) 64.1(12) 28.8(6) 65.7(10) 66.6(9)** 67.5(11)* 
† Indicates that the value correlated with the corresponding sIAD from Day 1, p<.05 
* Indicates that the value differed significantly from Day 1, p<.05 
** Indicates that the value differed significantly from Day 1, p<.005 
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Appendix F – Statistical Analyses for Chapter 2
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1a. One-way ANOVA between sequential and simultaneous right-arm SBP 
F-Statistic Degrees of Freedom Sig. 
0.017 71 0.897 
 
1b. One-way ANOVA between sequential and simultaneous right-arm DBP 
F-Statistic Degrees of Freedom Sig. 
0.016 71 0.899 
 
1c. One-way ANOVA between sequential and simultaneous left-arm SBP 
F-Statistic Degrees of Freedom Sig. 
0.686 71 0.410 
 
1d. One-way ANOVA between sequential and simultaneous left-arm DBP 
F-Statistic Degrees of Freedom Sig. 
0.000 71 0.992 
 
2a. Independent-samples Kolmogorov-Smirnov’s test for probability of distributions of pooled 
individual right arm and left arm SBP values 
Null Hypothesis 
Total 
N 
Test 
Statistic 
Asymptotic Sig. 
(2-Sided Test) 
Decision 
Distribution of pooled SBP is the same across categories 
of measurement side 
576 .458 .985 
Retain the null 
hypothesis 
 
2b. Independent-samples Kolmogorov-Smirnov’s test for probability of distributions of pooled 
individual right arm and left arm DBP values 
Null Hypothesis 
Total 
N 
Test 
Statistic 
Asymptotic Sig. 
(2-Sided Test) 
Decision 
Distribution of pooled DBP is the same across categories 
of measurement side 
576 1.292 .071 
Retain the null 
hypothesis 
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3a. Independent t-test for differences between means of sequential-first and simultaneous-first 
groups (i.e., test for order effects) from first-day, sequential sIADs 
 
Levene’s Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Error 
95% CI of the 
Diff 
Lower Upper 
D1 Seq. 
sIAD 
Equal Variances 
Assumed 
1.985 .178 .520 16 .610 1.26667 2.43693 -3.899 6.432 
 
Equal Variances 
not Assumed 
  N/A N/A N/A N/A N/A N/A N/A 
 
3b. Independent t-test for differences between means of sequential-first and simultaneous-first 
groups (i.e., test for order effects) from first-day, sequential dIADs 
 
Levene’s Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Error 
95% CI of the 
Diff 
Lower Upper 
D1 Seq. 
dIAD 
Equal Variances 
Assumed 
5.100 .038 N/A N/A N/A N/A N/A N/A N/A 
 
Equal Variances 
not Assumed 
  
-
2.601 
12.286 .023 -2.829 1.08757 -5.193 -.4667 
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3c. Independent t-test for differences between means of sequential-first and simultaneous-first 
groups (i.e., test for order effects) from first-day, simultaneous sIADs 
 
Levene’s Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Error 
95% CI of the 
Diff 
Lower Upper 
D1 Sim. 
sIAD 
Equal Variances 
Assumed 
.833 .375 
-
.591 
16 .563 
-
1.12083 
1.89518 -5.138 2.897 
 
Equal Variances 
not Assumed 
  N/A N/A N/A N/A N/A N/A N/A 
 
3d. Independent-samples Kolmogorov-Smirnov’s test for probability of distributions of 
sequential-first and simultaneous-first groups (i.e., test for order effects) from first-day, 
simultaneous dIADs  
Null Hypothesis 
Total 
N 
Test 
Statistic 
Asymptotic Sig. (2-
Sided Test) 
Distribution of first-day simultaneous dIADs is the same across 
categories of order 
18 .791 .560 
 
3e. Independent t-test for differences between means of sequential-first and simultaneous-first 
groups (i.e., test for order effects) from second-day, sequential sIADs 
 
Levene’s Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Error 
95% CI of the 
Diff 
Lower Upper 
D2 Seq. 
sIAD 
Equal Variances 
Assumed 
2.897 .108 
-
.302 
16 .766 
-
.53333 
1.76485 -4.275 3.208 
 
Equal Variances 
not Assumed 
  N/A N/A N/A N/A N/A N/A N/A 
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3f. Independent-samples Kolmogorov-Smirnov’s test for probability of distributions of 
sequential-first and simultaneous-first groups (i.e., test for order effects) from second-day, 
sequential dIADs 
Null Hypothesis 
Total 
N 
Test 
Statistic 
Asymptotic Sig. 
(2-Sided Test) 
Decision 
Distribution of second-day sequential dIADs is the same 
across categories of order 
18 1.845 .002 
Reject the null 
hypothesis 
 
3g. Independent t-test for differences between means of sequential-first and simultaneous-first 
groups (i.e., test for order effects) from second-day, simultaneous sIADs 
 
Levene’s Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Error 
95% CI of the 
Diff 
Lower Upper 
D2 Sim. 
sIAD 
Equal 
Variances 
Assumed 
.090 .768 .335 16 .742 .59167 1.76877 -3.158 4.341 
 
Equal 
Variances not 
Assumed 
  N/A N/A N/A N/A N/A N/A N/A 
 
3h. Independent t-test for differences between means of sequential-first and simultaneous-first 
groups (i.e., test for order effects) from second-day, simultaneous dIADs 
 
Levene’s Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Error 
95% CI of the 
Diff 
Lower Upper 
D2 Sim. 
dIAD 
Equal Variances 
Assumed 
.046 .832 
-
.382 
16 .707 -.60833 1.59153 -3.982 2.676 
 
Equal Variances 
not Assumed 
  N/A N/A N/A N/A N/A N/A N/A 
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4a. Clopper-Pearson binomial tests of proportions for first-day resting IADs 
Parameter Hypothesized Observed 
Standard 
Error 
Prevalence 95% CI Exact Sig. 
Seq. Sys.                
∆ > 5mmHg 
0 6 .134 .333 .133 - .590 1.845E-14 
Seq. Sys.                
∆ > 10mmHg 
0 1 .134 .056 .001 - .273 .018 
Seq. Dia.                
∆ > 5mmHg 
0 2 .134 .111 .014 - .347 1.514E-4 
Seq. Dia.                
∆ > 10mmHg 
0 0 .134 .000 .000 - .185 .982 
Sim. Sys.                
∆ > 5mmHg 
0 3 .134 .167 .036 - .414 8.069E-7 
Sim. Sys.                
∆ > 10mmHg 
0 2 .134 .111 .014 - .347 1.514E-4 
Sim. Dia.                
∆ > 5mmHg 
0 2 .134 .111 .014 - .347  1.514E-4 
Sim. Dia.                
∆ > 10mmHg 
0 0 .134 .000 .000 - .185 .982 
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4b. Clopper-Pearson binomial tests of proportions for second-day resting IADs 
Parameter Hypothesized Observed 
Standard 
Error 
Prevalence 95% CI Exact Sig. 
Seq. Sys.                
∆ > 5mmHg 
0 5 .134 .278 .097 - .535 8.476E-12 
Seq. Sys.                
∆ > 10mmHg 
0 0 .134 .000 .000 - .185 .982 
Seq. Dia.                
∆ > 5mmHg 
0 0 .134 .000 .000 - .185 .982 
Seq. Dia.                
∆ > 10mmHg 
0 0 .134 .000 .000 - .185 .982 
Sim. Sys.                
∆ > 5mmHg 
0 5 .134 .278 .097 - .535 8.476E-12 
Sim. Sys.                
∆ > 10mmHg 
0 0 .134 .000 .000 - .185 .982 
Sim. Dia.                
∆ > 5mmHg 
0 3 .134 .167 .036 - .414 8.069E-7 
Sim. Dia.                
∆ > 10mmHg 
0 0 .134 .000 .000 - .185 .982 
 
4c. Clopper-Pearson binomial tests of proportions for first-day ambulatory IADs 
Parameter Hypothesized Observed 
Standard 
Error 
Prevalence 95% CI Exact Sig. 
Seq. Sys.                
∆ > 5mmHg 
0 11 .134 .611 .357 - .827 2.220E-16 
Seq. Sys.                
∆ > 10mmHg 
0 6 .134 .333 .133 - .590 1.845E-14 
Seq. Sys.                
∆ > 15mmHg 
0 2 .134 .111 .014 - .347 1.514E-4 
Seq. Sys.                
∆ > 20mmHg 
0 1 .134 .056 .001 - .273 .018 
Seq. Dia.                
∆ > 5mmHg 
0 4 .134 .222 .064 - .476 3.026E-9 
Seq. Dia.                
∆ > 10mmHg 
0 1 .134 .056 .001 - .273 .018 
 
99 
 
4d. Clopper-Pearson binomial tests of proportions for second-day ambulatory IADs 
Parameter Hypothesized Observed 
Standard 
Error 
Prevalence 95% CI Exact Sig. 
Seq. Sys.                
∆ > 5mmHg 
0 8 .134 .611 .357 - .827 2.220E-16 
Seq. Sys.                
∆ > 10mmHg 
0 1 .134 .056 .001 - .273 .018 
Seq. Sys.                
∆ > 15mmHg 
0 0 .134 .000 .000 - .185 .982 
Seq. Sys.                
∆ > 20mmHg 
0 0 .134 .000 .000 - .185 .982 
Seq. Dia.                
∆ > 5mmHg 
0 2 .134 .111 .014 - .347 1.514E-4 
Seq. Dia.                
∆ > 10mmHg 
0 0 .134 .000 .000 - .185 .982 
 
5a. Two-way random intraclass correlation between first- and second-day resting, sequential 
sIADs 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.131 -.345 - .553 1.300 17 17 .297 
 
5b. Two-way random intraclass correlation between first- and second-day resting, sequential 
dIADs 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.327 -.151 - .6.81 1.927 17 17 .086 
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5c. Two-way random intraclass correlation between first- and second-day resting, simultaneous 
sIADs 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.148 -.330 - .565 1.347 17 17 .273 
 
5d. Two-way random intraclass correlation between first- and second-day resting, simultaneous 
dIADs 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.561 .142 - .810 3.559 17 17 .006 
 
5e. Two-way random intraclass correlation between first- and second-day ambulatory sIADs 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.472 .020 - .763 2.785 17 17 .021 
 
5f. Two-way random intraclass correlation between first- and second-day ambulatory dIADs 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.264 -.218 - .642 1.716 17 17 .138 
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6a. McNemar’s test of binomial distributions for between-days comparisons of resting, sequential 
sIAD and dIAD prevalence 
Parameter Null Hypothesis 
Total 
N 
Test 
Statistic 
Degrees 
of 
Freedom 
Exact Sig. 
(2-Sided 
Test) 
Decision 
Seq. Sys.                
∆ > 5mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.167 1 0.688 
Retain the 
null 
Seq. Sys.                
∆ > 10mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.500 1 0.500 
Retain the 
null 
Seq. Sys.                
∆ > 15mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Seq. Sys.                
∆ > 20mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Seq. Dia.                
∆ > 5mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.500 1 0.500 
Retain the 
null 
Seq. Dia.                
∆ > 10mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Seq. Dia.                
∆ > 15mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Seq. Dia.                
∆ > 20mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
** Test statistic and significance could not be computed because there were 0 cases exceeding these 
thresholds. 
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6b. McNemar’s test of binomial distributions for between-days comparisons of resting, 
simultaneous sIAD and dIAD prevalence 
Parameter Null Hypothesis 
Total 
N 
Test 
Statistic 
Degrees 
of 
Freedom 
Exact Sig. 
(2-Sided 
Test) 
Decision 
Sim. Sys.                
∆ > 5mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.167 1 0.688 
Retain the 
null 
Sim. Sys.                
∆ > 10mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.500 1 0.500 
Retain the 
null 
Sim. Sys.                
∆ > 15mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Sim. Sys.                
∆ > 20mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Sim. Dia.                
∆ > 5mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.000 1 1.000 
Retain the 
null 
Sim. Dia.                
∆ > 10mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Sim. Dia.                
∆ > 15mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Sim. Dia.                
∆ > 20mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
** Test statistic and significance could not be computed because there were 0 cases exceeding these 
thresholds. 
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6c. McNemar’s test of binomial distributions for between-days comparisons of ambulatory, 
sequential sIAD and dIAD prevalence 
Parameter Null Hypothesis 
Total 
N 
Test 
Statistic 
Degrees 
of 
Freedom 
Exact Sig. 
(2-Sided 
Test) 
Decision 
Seq. Sys.                
∆ > 5mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.444 1 0.508 
Retain the 
null 
Seq. Sys.                
∆ > 10mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 3.200 1 0.063 
Retain the 
null 
Seq. Sys.                
∆ > 15mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.500 1 0.500 
Retain the 
null 
Seq. Sys.                
∆ > 20mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.000 1 1.000 
Retain the 
null 
Seq. Dia.                
∆ > 5mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.167 1 0.688 
Retain the 
null 
Seq. Dia.                
∆ > 10mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 0.000 1 1.000 
Retain the 
null 
Seq. Dia.                
∆ > 15mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
Seq. Dia.                
∆ > 20mmHg 
Distributions across sequential 
and simultaneous are equally 
likely 
18 .** 1 .** .** 
** Test statistic and significance could not be computed because there were 0 cases exceeding these thresholds. 
 
7a. Pearson’s correlation between first-day State Anxiety scores and first-day resting, sequential 
sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
-.338 .171 
D1 Seq. sIAD -1.00000 4.999346 18 
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7b. Pearson’s correlation between first-day State Anxiety scores and first-day resting, sequential 
dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
-.287 .248 
D1 Seq. dIAD -1.66667 2.807553 18 
 
7c. Pearson’s correlation between first-day State Anxiety scores and first-day resting, 
simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
-.249 .320 
D1 Sim. sIAD .23148 4.023273 18 
 
7d. Pearson’s correlation between first-day State Anxiety scores and first-day resting, 
simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
-.084 .740 
D1 Sim. dIAD -1.81481 2.926602 18 
 
7e. Pearson’s correlation between second-day State Anxiety scores and second-day resting, 
sequential sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.029 .908 
D2 Seq. sIAD .01852 3.733740 18 
 
7f. Pearson’s correlation between second-day State Anxiety scores and second-day resting, 
sequential dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.177 .482 
D2 Seq. dIAD -1.03704 2.141678 18 
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7g. Pearson’s correlation between second-day State Anxiety scores and second-day resting, 
simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
-.046 .857 
D2 Sim. sIAD .222222 4.157048 18 
 
7h. Pearson’s correlation between second-day State Anxiety scores and second-day resting, 
simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.183 .467 
D2 Sim. dIAD -1.33333 2.856022 18 
 
7i. Pearson’s correlation between first-day State Anxiety scores and first-day ambulatory sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
.486 .041 
D1 Amb. sIAD 3.12963 9.416394 18 
 
7j. Pearson’s correlation between first-day State Anxiety scores and first-day ambulatory dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
.344 .162 
D1 Amb. dIAD -.27778 4.435817 18 
 
7k. Pearson’s correlation between second-day State Anxiety scores and second-day ambulatory 
sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.356 .147 
D2 Amb. sIAD .62963 5.896591 18 
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7l. Pearson’s correlation between second-day State Anxiety scores and second-day ambulatory 
dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.123 .628 
D2 Amb. dIAD -1.31481 3.062470 18 
 
8a. Pearson’s correlation between first-day sequential heart rate and first-day resting, sequential 
sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 Seq. HR 63.0417 10.23673 16 
-.538 .032 
D1 Seq. sIAD -1.00000 4.999346 18 
 
8b. Pearson’s correlation between first-day sequential heart rate and first-day resting, sequential 
dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 Seq. HR 63.0417 10.23673 16 
-.315 .235 
D1 Seq. dIAD -1.66667 2.807553 18 
 
8c. Pearson’s correlation between first-day simultaneous heart rate and first-day resting, 
simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 Sim. HR 63.0625 9.36263 16 
-.401 .124 
D1 Sim. sIAD .23148 4.023273 18 
 
8d. Pearson’s correlation between first-day simultaneous heart rate and first-day resting, 
simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 Sim. HR 63.0625 9.36263 16 
-.296 .265 
D1 Sim. dIAD -1.81481 2.926602 18 
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8e. Pearson’s correlation between second-day sequential heart rate and second-day resting, 
sequential sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 Seq. HR 65.7187 9.78656 16 
-.458 .074 
D2 Seq. sIAD .01852 3.733740 18 
 
8f. Pearson’s correlation between second-day sequential heart rate and second-day resting, 
sequential dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 Seq. HR 65.7187 9.78656 16 
.017 .949 
D2 Seq. dIAD -1.03704 2.141678 18 
 
8g. Pearson’s correlation between second-day simultaneous heart rate and second-day resting, 
simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 Sim. HR 66.5937 8.79604 16 
-.145 .593 
D2 Sim. sIAD .22222 4.157048 18 
 
8h. Pearson’s correlation between second-day simultaneous heart rate and second-day resting, 
simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 Sim. HR 66.5937 8.79604 16 
-.220 .414 
D2 Sim. dIAD -1.33333 2.856022 18 
 
8i. Pearson’s correlation between first-day ambulatory heart rate and first-day ambulatory sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 Amb. HR 64.1019 11.65874 18 
-.012 .964 
D1 Amb. sIAD 3.12963 9.416394 18 
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8j. Pearson’s correlation between first-day ambulatory heart rate and first-day ambulatory dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 Amb. HR 64.1019 11.65874 18 
-.188 .456 
D1 Amb. dIAD -2.7778 4.435817 18 
 
8k. Pearson’s correlation between second-day ambulatory heart rate and second-day ambulatory 
sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 Amb. HR 67.4907 10.96675 18 
-.045 .832 
D2 Amb. sIAD .62963 5.896591 18 
 
8l. Pearson’s correlation between second-day ambulatory heart rate and second-day ambulatory 
dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 Amb. HR 67.4907 10.96675 18 
.011 .965 
D2 Amb. dIAD -1.31481 3.062470 18 
 
9a. Pearson’s correlation between Body Mass Index and first-day sequential sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.004 .987 
D1 Seq. sIAD -1.00000 4.999346 18 
 
9b. Pearson’s correlation between Body Mass Index and first-day sequential dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.183 .468 
D1 Seq. dIAD -1.66667 2.807553 18 
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9c. Pearson’s correlation between Body Mass Index and first-day simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
.089 .725 
D1 Sim. sIAD .23148 4.023273 18 
 
9d. Pearson’s correlation between Body Mass Index and first-day simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.351 .153 
D1 Sim. dIAD -1.81481 2.926602 18 
 
9e. Pearson’s correlation between Body Mass Index and second-day sequential sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
.044 .861 
D2 Seq. sIAD .01852 3.733740 18 
 
9f. Pearson’s correlation between Body Mass Index and second-day sequential dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.405 .096 
D2 Seq. dIAD -1.03704 2.141678 18 
 
9g. Pearson’s correlation between Body Mass Index and second-day simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.243 .332 
D2 Sim. sIAD .22222 4.157048 18 
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9h. Pearson’s correlation between Body Mass Index and second-day simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.481 .043 
D2 Sim. dIAD -1.33333 2.856022 18 
 
9i. Pearson’s correlation between Body Mass Index and first-day ambulatory sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.007 .978 
D1 Amb. sIAD 3.12963 6.416394 18 
 
9j. Pearson’s correlation between Body Mass Index and first-day ambulatory dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
.050 .845 
D1 Amb. dIAD -.27778 4.435817 18 
 
9k. Pearson’s correlation between Body Mass Index and second-day ambulatory sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.237 .343 
D2 Amb. sIAD .62963 5.896591 18 
 
9l. Pearson’s correlation between Body Mass Index and second-day ambulatory dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
BMI 25.2725 4.51879 18 
-.188 .455 
D2 Amb. dIAD -1.31481 3.062470 18 
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10a. Spearman’s Rho correlation between age and first-day sequential sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.054 .832 
D1 Seq. sIAD -1.00000 4.999346 18 
 
10b. Spearman’s Rho correlation between age and first-day sequential dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.418 .084 
D1 Seq. dIAD -1.66667 2.807553 18 
 
10c. Spearman’s Rho correlation between age and first-day simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.357 .146 
D1 Sim. sIAD .23148 4.023273 18 
 
10d. Spearman’s Rho correlation between age and first-day simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.408 .095 
D1 Sim. dIAD -1.81481 2.926602 18 
 
10e. Spearman’s Rho correlation between age and second-day sequential sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.373 .128 
D2 Seq. sIAD .01852 3.733740 18 
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10f. Spearman’s Rho correlation between age and second-day sequential dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.270 .279 
D2 Seq. dIAD -1.03704 2.141678 18 
 
10g. Spearman’s Rho correlation between age and second-day simultaneous sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
.102 .687 
D2 Sim. sIAD .22222 4.157048 18 
 
10h. Spearman’s Rho correlation between age and second-day simultaneous dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.220 .381 
D2 Sim. dIAD -1.33333 2.856022 18 
 
10i. Spearman’s Rho correlation between age and first-day ambulatory sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
.087 .732 
D1 Amb. sIAD 3.12963 6.416394 18 
  
10j. Spearman’s Rho correlation between age and first-day ambulatory dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
-.040 .874 
D1 Amb. dIAD -.27778 4.435817 18 
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10k. Spearman’s Rho correlation between age and second-day ambulatory sIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
.032 .900 
D2 Amb. sIAD .62963 5.896591 18 
 
10l. Spearman’s Rho correlation between age and second-day ambulatory dIADs 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
Age 24.72 4.363 18 
.041 .872 
D2 Amb. dIAD -1.31481 3.062470 18 
 
11a. Paired t-test for differences between first- and second-day State Anxiety means 
Paired Differences 
t df Sig. (2-tailed) Mean 
  95% CI 
Std. Deviation Std. Error Lower Upper 
1.22222 5.40757 1.27458 -1.46690 3.91134 .959 17 .138 
 
11b. Paired t-test for differences between first- and second-day resting, sequential heart rate 
means 
Paired Differences 
t df Sig. (2-tailed) Mean 
  95% CI 
Std. Deviation Std. Error Lower Upper 
-2.67708 5.39838 1.34959 -5.55368 1.9958 -1.984 15 .066 
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11c. Paired t-test for differences between first- and second-day resting, simultaneous heart rate 
means 
Paired Differences 
t df Sig. (2-tailed) Mean 
  95% CI 
Std. Deviation Std. Error Lower Upper 
-3.53125 4.11241 1.02810 -5.72260 -1.33990 -3.435 15 .004 
 
11d. Paired t-test for differences between first- and second-day ambulatory heart rate means 
Paired Differences 
t df Sig. (2-tailed) Mean 
  95% CI 
Std. Deviation Std. Error Lower Upper 
-3.38889 6.17719 1.45598 -6.46073 -.31704 -2.328 17 .033 
 
12a. Two-way random intraclass correlation between first- and second-day State Anxiety scores 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.717 .388 - .884 6.069 17 17 .000 
 
12b. Two-way random intraclass correlations between first- and second-day sequential heart rate 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.855 .634 - .947 12.765 15 15 .000 
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12c. Two-way random intraclass correlations between first- and second-day simultaneous heart 
rate 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.898 .732 - .963 18.516 15 15 .000 
 
12d. Two-way random intraclass correlations between first- and second-day ambulatory heart rate 
 
ICC F Test with True Value 0 
Coefficient 95% CI Value df1 df2 Significance 
Single 
Measure 
.851 .646 - .942 12.428 17 17 .000 
 
13a. Pearson’s correlation between first-day State Anxiety scores and sequential heart rate 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
.356 .175 
D1 Seq. HR 63.0417 10.23673 16 
 
13b. Pearson’s correlation between first-day State Anxiety scores and simultaneous heart rate 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
.340 .197 
D1 Sim. HR 63.0625 9.36263 16 
 
13c. Pearson’s correlation between second-day State Anxiety scores and sequential heart rate 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.496 .051 
D2 Seq. HR 65.7187 9.78656 16 
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13d. Pearson’s correlation between second-day State Anxiety scores and simultaneous heart rate 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.379 .148 
D2 Sim. HR 66.5937 8.79604 16 
 
13e. Pearson’s correlation between first-day State Anxiety score and ambulatory heart rate 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D1 State Score 30.0000 7.95576 18 
.138 .586 
D1 Amb. HR 64.1019 11.65874 18 
 
13f. Pearson’s correlation between second-day State Anxiety score and ambulatory heart rate 
 Mean Std. Deviation N Correlation Sig. (2-tailed) 
D2 State Score 28.7778 6.32972 18 
.343 .164 
D2 Amb. HR 67.4907 10.96675 18 
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